

CHEMICALS AND PHARMACEUTICALS

8. Chemicals and Pharmaceuticals

As on 31.03.2016, there were 16 Central Public Sector Enterprises in the Chemicals and Pharmaceuticals group. The names of these enterprises along with their year of incorporation in chronological order are given below: -

S. No.	Enterprise	Year of Incorporation
1	HINDUSTAN ANTIBIOTICS LTD.	1954
2	HINDUSTAN INSECTICIDES LTD.	1954
3	HINDUSTAN ORGANIC CHEMICALS LTD.	1960
4	INDIAN DRUGS & PHARMACEUTICALS LTD.	1961
5	RAJASTHAN DRUGS & PHARMACEUTICALS LTD.	1978
6	INDIAN MEDICINES & PHARMACEUTICAL CORPN. LTD.	1978
7	ORISSA DRUGS & CHEMICALS LTD.	1979
8	BENGAL CHEMICALS & PHARMACEUTICALS LTD.	1901
9	KARNATAKA ANTIBIOTICS & PHARMACEUTICALS LTD.	1981
10	HINDUSTAN FLUOROCARBONS LIMITED	1983
11	BHARAT IMMUNOLOGICALS & BIOLOGICALS CORP. LTD.	1989
12	IDPL (TAMILNADU) LTD.	1994
13	BRAHAMPUTRA CRACKERS & POLYMER LTD.	2007
14	GOA ANTIBIOTICS & PHARMACEUTICALS LTD.	1980
15	HLL BIOTECH LTD.	2012
16	ONGC MANGALORE PETROCHEMICALS LTD.	2015

2. The enterprises falling in this group are mainly engaged in producing and selling of pharmaceuticals, surgical instruments, and ayurvedic intermediates, pesticide etc.

3. The consolidated financial position, the working results and the important management ratios of these enterprises are appended.

4. **Turnover:** The details of turnover of individual enterprises are given below:

(₹ in Crore)

S. No.	Enterprise	Turnover	
		2015-16	2014-15
1	BENGAL CHEMICALS & PHARMACEUTICALS LTD.	96.23	49.58
2	BHARAT IMMUNOLOGICALS & BIOLOGICALS CORP. LTD.	128.03	146.24
3	BRAHAMPUTRA CRACKERS & POLYMER LTD.	1.92	0
4	GOA ANTIBIOTICS & PHARMACEUTICALS LTD.	50.59	49.43
5	HINDUSTAN ANTIBIOTICS LTD.	15.12	18.54
6	HINDUSTAN FLUOROCARBONS LIMITED	39.63	32.75
7	HINDUSTAN INSECTICIDES LTD.	334.75	339.91
8	HINDUSTAN ORGANIC CHEMICALS LTD.	120.81	168.31
9	HLL BIOTECH LTD.	0.06	1.15
10	IDPL (TAMILNADU) LTD.	9.04	8.12
11	INDIAN DRUGS & PHARMACEUTICALS LTD.	87.14	63.55
12	INDIAN MEDICINES & PHARMACEUTICAL CORPN. LTD.	36.3	32.03
13	KARNATAKA ANTIBIOTICS & PHARMACEUTICALS LTD.	329.54	249.17
14	ONGC MANGALORE PETROCHEMICALS LTD.	4187.57	0
15	ORISSA DRUGS & CHEMICALS LTD.	21.24	19.09
16	RAJASTHAN DRUGS & PHARMACEUTICALS LTD.	36.53	24.9
SUB TOTAL :		5494.5	1202.77

5. **Net Profit / Loss:** The details of enterprises, which earned net

profit or sustained net loss (-) are given below:

(₹ in Crore)

S. No.	Enterprise	Net Profit/ Loss	
		2015-16	2014-15
1	BENGAL CHEMICALS & PHARMACEUTICALS LTD.	-9.13	-17.32
2	BHARAT IMMUNOLOGICALS & BIOLOGICALS CORP. LTD.	-6.21	1.55
3	BRAHAMPUTRA CRACKERS & POLYMER LTD.	-270.23	0
4	GOA ANTIBIOTICS & PHARMACEUTICALS LTD.	2.3	1.8
5	HINDUSTAN ANTIBIOTICS LTD.	-77.18	-70.55
6	HINDUSTAN FLUOROCARBONS LIMITED	-11.11	-3.77
7	HINDUSTAN INSECTICIDES LTD.	1.83	1.6
8	HINDUSTAN ORGANIC CHEMICALS LTD.	-173.91	-215.49
9	HLL BIOTECH LTD.	-0.63	-0.07
10	IDPL (TAMILNADU) LTD.	-0.73	1.12
11	INDIAN DRUGS & PHARMACEUTICALS LTD.	-166.08	-167.21
12	INDIAN MEDICINES & PHARMACEUTICAL CORPN. LTD.	-3.32	-0.14
13	KARNATAKA ANTIBIOTICS & PHARMACEUTICALS LTD.	19.51	11.06
14	ONGC MANGALORE PETROCHEMICALS LTD.	-875.35	0
15	ORISSA DRUGS & CHEMICALS LTD.	1.46	1.35
16	RAJASTHAN DRUGS & PHARMACEUTICALS LTD.	-5.99	-19.76
SUB TOTAL :		-1574.77	-475.83

6. **Dividend:** The details of dividend declared by the individual enterprises are given below:

(₹ in Crore)

S. No.	Enterprise	Dividend	
		2015-16	2014-15
1	KARNATAKA ANTIBIOTICS & PHARMACEUTICALS LTD.	2.02	1.89
SUB TOTAL :		2.02	1.89

7. **Social Overhead and Township:** The total number of persons employed and the expenditure incurred on social overheads and townships are given below:

S. No.	Particulars	Township and Social Overheads	
		2015-16	2014-15
1	No. of employees (in number)	6283	5951
2	Social overheads: (₹ in Crore)		
	(i) Educational	2.57	9.93
	(ii) Medical Facilities	8.02	10.98
	(iii) Others	10.25	12.36
3	Capital cost of township (₹ in Crore)	133.22	66.98
4	No. of houses constructed (in numbers)	2574	1791

8. Company wise details in respect of Balance Sheet, Profit and Loss Account, Important Indicators and Financial Ratios along with the write up of individual company are given in the page below

CHEMICALS & PHARMACEUTICALS

BALANCE SHEET	(₹ in Lakhs)		
PARTICULARS	2015-16	2014-15	2013-14
I. EQUITY & LIABILITIES			
AUTHORISED CAPITAL	525760	325760	315260
(1) Shareholders' Funds			
(a) Share Capital			
(i) Central Govt	264248	75658	75657
(ii) Others	153280	143591	139508
(b) Reserves & Surplus	-614764	-401534	-353528
(c) Money received against share warrants	0	0	0
Total Shareholders' Funds (1(a)+1(b)+1(c))	-197236	-182285	-138363
(2) Share application money pending allotment	17	5744	5828
(3) Non-current Liabilities			
(a) Long Term Borrowings	1110729	793192	674106
(b) Deferred tax liabilities (Net)	750	28	0
(c) Other Long-term liabilities	12372	11433	11159
(d) Long-term provisions	22699	21601	19387
Total Non-Current Liabilities 3(a) to 3(d)	1146550	826254	704652
(4) Current Liabilities			
(a) Short Term Borrowings	606841	206022	208292
(b) Trade Payables	142537	72083	69762
(c) Other current liabilities	206905	127346	104002
(d) Short-term provisions	50918	36062	33842
Total Current Liabilities 4(a) to 4(d)	1007201	441513	415898
TOTAL EQUITY & LIABILITIES (1+2+3+4)	1956532	1091226	988015
II. ASSETS			
(1) Non-Current Assets			
(a) Total Gross Fixed Assets	1716968	179894	176323
(ai) Accumulated Depreciation, Depletion & Amortisation	171619	111393	110658
(aii) Accumulated Impairment	1594	248	234
(b) Total Net Fixed Assets ((a)-(ai)-(aii))	1543755	68253	65431
(c) Capital work in progress	81390	594165	582017
(d) Intangible assets under developmet	1015	709	311
(e) Non-Current Investments	4015	3967	4188
(f) Deferred Tax Assets (Net)	800	415	854
(g) Long Term Loans and Advances	76700	269494	181779
(h) Other Non-Current Assets	1959	2347	2017
Total Non-Current Assets (b+c+d+e+f+g+h)	1709634	939350	836597
(2) Current Assets			
(a) Current Investments	0	0	0
(b) Inventories	74670	30614	24905
(c) Trade Recievables	60242	37883	37629
(d) Cash & Bank Balance	32010	41708	41734
(e) Short-term Loans & Advances	55860	23812	26607
(f) Other Current Assets	24116	17859	20543
Total Current Assets (a+b+c+d+e+f)	246898	151876	151418
TOTAL ASSETS (1+2)	1956532	1091226	988015
Important Indicators			
(i) Investment	1528274	1018185	895099
(ii) Capital Employed	913510	616651	541571
(iii) Net Worth	-203495	-176541	-132535
(iv) Net Current Assets	-760303	-289637	-264480
(v) Cost of Sales	623829	140458	146895
(vi) Net Value Added (at market price)	-6681	34642	-69997
(vii) Total Regular Employees (Nos.)	6283	5951	6473
(viii) Avg. Monthly Emoluments per Employee(₹)	60731	58136	51407

PROFIT & LOSS ACCOUNT	(₹ in Lakhs)		
PARTICULARS	2015-16	2014-15	2013-14
(I) Revenue from Operations (Gross)	549450	120277	127122
Less : Excise Duty	6539	6455	8084
Revenue from Operations (Net)	542911	113822	119038
(II) Other Income	10870	6834	6676
(III) Total Revenue (I+II)	553781	120656	125714
(IV) Expenditure on:			
(a) Cost of materials consumed	430276	59522	64147
(b) Purchase of stock-in-trade	6584	5769	6888
(c) Changes in inventories of finished goods, work-in-progress and stock in trade	12570	-4882	450
(d) Stores & Spares	1747	1982	1209
(e) Power & Fuel	48952	8591	10364
(f) Salary, Wages & Benefits/Employees Expense	45789	41516	39931
(g) Other Operating/direct/manufacturing Expenses	16586	11040	8821
(h) Rent, Royalty & Cess	588	299	244
(i) Loss on sale of Assets/Investments	0	1	185
(j) Other Expenses	16890	13420	10969
Total Expenditure (IV (a to j))	579982	137258	143208
(V) PROFIT BEFORE DEPRECIATION, & IMPAIRMENT, FINANCE CHARGES/INTEREST, EXCEPTIONAL & EXTRAORDINARY ITEMS & TAXES (PBDIET)(III-IV)	-26201	-16602	-17494
(VI) Depreciation, Depletion & Amortisation	42253	3187	3767
(VII) Impairment	1594	14	105
(VIII) PROFIT BEFORE FINANCE COST/INTEREST, EXCEPTIONAL, EXTRA-ORDINARY ITEMS & TAXES (PBIET)(V-VI-VII)	-70048	-19803	-21366
(IX) Finance Cost			
(a) On Central Government Loans	30963	19792	20330
(b) On Foreign Loans	0	0	0
(c) Others	72412	7749	7078
(d) Less Finance Cost Capitalised	18218	6	140
(e) Charged to P & L Account (a+b+c -d)	85157	27535	27268
(X) PROFIT BEFORE EXCEPTIONAL & EXTRA-ORDINARY ITEMS & TAX (PBEET)(VIII-IXe)	-155205	-47338	-48634
(XI) Exceptional Items	66	-472	434
(XII) PROFIT BEFORE EXTRA-ORDINARY ITEMS & TAX (PBET)(X-XI)	-155271	-46866	-49068
(XIII) Extra-Ordinary Items	584	0	10
(XIV) PROFIT BEFORE TAX (PBT)(XII-XIII)	-155855	-46866	-49078
(XV) TAX PROVISIONS	1622	717	752
(XVI) NET PROFIT / LOSS FOR THE PERIOD FROM CONTINUING OPERATIONS AFTER TAX(XIV-XV)	-157477	-47583	-49830
(XVII) Profit/Loss from discontinuing operations	0	0	0
(XVIII) Tax expenses of discontinuing operations	0	0	0
(XIX) Profit/Loss from discontinuing operations (after Tax)(XVII-XVIII)	0	0	0
(XX) Profit/Loss for the period (XVI+XIX)	-157477	-47583	-49830
Financial Ratios			
(i) Sales : Capital Employed	59.43	18.46	21.98
(ii) Cost of Sales : Sales	114.9	123.4	123.4
(iii) Salary/Wages : Sales	8.43	36.47	33.54
(iv) Net Profit : Net Worth	-	-	-
(v) Debt : Equity	2.66	3.53	3.05
(vi) Current Ratio	0.25	0.34	0.36
(vii) Trade Recievables : Sales	11.1	33.28	31.61
(viii) Total Inventory : Sales	13.75	26.9	20.92

Bengal Chemicals & Pharmaceuticals Limited

6, Ganesh Chunder Avenue, Kolkata, West Bengal - 700013
www.bengalchemicals.co.in

The Company

Bengal Chemicals & Pharmaceuticals Limited (BCPL) was established in 1901 and incorporated as CPSE on 27.3.1981 with the objective to save the company from closure and to support the health programmes of the Government by providing quality medicines at reasonable price, to bridge the gap between demand and supply of life saving drugs and vaccines and to set up and develop Multi Disciplinary Research and Development Centre, inventing new molecules, processes and home products.

BCPL is a schedule 'C' BIFR referred, taken over CPSE in Chemicals & Pharmaceuticals Sector, under the administrative control of M/o Chemicals and Fertilizers, D/o Pharmaceuticals with 100% shareholding by the Government of India. The company employed 370 regular employees (Executives- 181 and Non-executives -189) as on 31.3.2016. Its registered and corporate offices are at Kolkata, West Bengal.

Vision / Mission

The vision / mission of the company are to cater to the needs of consumers for medicines, life saving drugs, chemical and home products.

Industrial / Business Operations

BCPL is involved in manufacturing and sale of pharmaceutical formulations, chemicals, cosmetics and home products. The company has 4 factories in Kolkata, Mumbai and Kanpur, 7 depots and 10 C&F agents throughout India.

Its products range has been classified in three divisions, viz. (i) Chemicals, (ii) Pharmaceutical formulations and (iii) Cosmetics & home products. The company produces Ferric Alum under chemical division. Life saving injectables like snake venom antiserum (AVS), Spirituous & Non-steroid anti inflammatory drugs in various dosage forms, Systemic alkaliser, Enzymes, etc. under pharmaceutical formulations division. In Cosmetics & home products division, Cantharidine hair oil, Pheneol, Klin toilet (Toilet cleaner), Naphthalene ball, Bleaching powder are produced.

Performance Highlights

The physical performance of the company during the last three years is given below:

Main Product / Services	Unit	Performance during		
		2015-16	2014-15	2013-14
Tablets & Capsules	Cr.	6.39	3.80	0.05
Disinfectant formulation	MT	1718	1597	1391
Chemical	MT	4082	5332	2518
Ointment	KL	25.06	43.79	13.15

Total revenue of the company registered an increase of ₹46.39 crore during 2015-16, which went up to ₹111.92 crore in 2015-16 from 65.53 crore in 2014-15 (Fig.1). The losses of the company has also gone down by ₹8.19 crore to ₹(-) 9.13 crore in 2015-16 from ₹(-) 17.32 crore in previous year.

Return on net worth and net profit ratio of the company is negative. The current ratio of company is at 0.63:1 during 2015-16 and 2014-15. Balance Sheet and Profit & Loss Account of the company and selected financial ratios during the period 2013-14 to 2015-16 can be seen on the adjoining page.




Fig.1

Strategic issue

All the pharma units are governed by Drugs & Cosmetics Act. The company had to comply with the norms of Schedule 'M' which was compiled by the company since 2007. Modernisation and renovation of factories is under progress.

BENGAL CHEMICALS & PHARMACEUTICALS LTD.

BALANCE SHEET	(₹ in Lakhs)		
PARTICULARS	2015-16	2014-15	2013-14
I. EQUITY & LIABILITIES			
AUTHORISED CAPITAL	8000	8000	8000
(1) Shareholders' Funds			
(a) Share Capital			
(i) Central Govt	7696	7696	7696
(ii) Others	0	0	0
(b) Reserves & Surplus	-18357	-17444	-16926
(c) Money received against share warrants	0	0	0
Total Shareholders' Funds (1(a)+1(b)+1(c))	-10661	-9748	-9230
(2) Share application money pending allotment	0	0	0
(3) Non-current Liabilities			
(a) Long Term Borrowings	19858	18588	16727
(b) Deferred tax liabilities (Net)	0	0	0
(c) Other Long-term liabilities	444	495	398
(d) Long-term provisions	1813	1699	1328
Total Non-Current Liabilities 3(a) to 3(d)	22115	20782	18453
(4) Current Liabilities			
(a) Short Term Borrowings	1882	2557	2529
(b) Trade Payables	4542	4302	0
(c) Other current liabilities	4330	4486	8136
(d) Short-term provisions	160	223	383
Total Current Liabilities 4(a) to 4(d)	10914	11568	11048
TOTAL EQUITY & LIABILITIES (1+2+3+4)	22368	22602	20271
II. ASSETS			
(1) Non-Current Assets			
(a) Total Gross Fixed Assets	12501	6686	6519
(ai) Accumulated Depreciation, Depletion & Amortisation	2765	2370	3225
(aii) Accumulated Impairment	0	0	0
(b) Total Net Fixed Assets ((a)-(ai)-(aii))	9736	4316	3294
(c) Capital work in progress	5718	10923	10973
(d) Intangible assets under developmet	0	0	0
(e) Non-Current Investments	0	0	0
(f) Deferred Tax Assets (Net)	0	0	0
(g) Long Term Loans and Advances	29	25	32
(h) Other Non-Current Assets	0	0	0
Total Non-Current Assets (b+c+d+e+f+g+h)	15483	15264	14299
(2) Current Assets			
(a) Current Investments	0	0	0
(b) Inventories	1463	1429	811
(c) Trade Recievables	2633	1440	743
(d) Cash & Bank Balance	1865	3698	3009
(e) Short-term Loans & Advances	476	539	1109
(f) Other Current Assets	448	232	300
Total Current Assets (a+b+c+d+e+f)	6885	7338	5972
TOTAL ASSETS (1+2)	22368	22602	20271
Important Indicators			
(i) Investment	27554	26284	24423
(ii) Capital Employed	9197	8840	7497
(iii) Net Worth	-10661	-9748	-9230
(iv) Net Current Assets	-4029	-4230	-5076
(v) Cost of Sales	10547	7824	6033
(vi) Net Value Added (at market price)	4242	3370	410
(vii) Total Regular Employees (Nos.)	370	405	481
(viii) Avg. Monthly Emoluments per Employeee(₹)	51081	58786	39518
2015-16 PROVISIONAL			

PROFIT & LOSS ACCOUNT	(₹ in Lakhs)		
PARTICULARS	2015-16	2014-15	2013-14
(I) Revenue from Operations (Gross)	9623	4958	1904
Less : Excise Duty	804	375	197
Revenue from Operations (Net)	8819	4583	1707
(II) Other Income	2373	1970	1956
(III) Total Revenue (I+II)	11192	6553	3663
(IV) Expenditure on:			
(a) Cost of materials consumed	5590	3532	1245
(b) Purchase of stock-in-trade	0	0	0
(c) Changes in inventories of finished goods, work-in-progress and stock in trade	40	-508	209
(d) Stores & Spares	80	72	65
(e) Power & Fuel	190	158	111
(f) Salary, Wages & Benefits/Employees Expense	2268	2857	2281
(g) Other Operating/direct/manufacturing Expenses	989	137	133
(h) Rent, Royalty & Cess	0	0	0
(i) Loss on sale of Assets/Investments	0	0	0
(j) Other Expenses	995	1215	1655
Total Expenditure (IV (a to j))	10152	7463	5699
(V) PROFIT BEFORE DEPRECIATION, & IMPAIRMENT, FINANCE CHARGES/INTEREST, EXCEPTIONAL & EXTRAORDINARY ITEMS & TAXES (PBDIET)(III-IV)	1040	-910	-2036
(VI) Depreciation, Depletion & Amortisation	395	361	334
(VII) Impairment	0	0	0
(VIII) PROFIT BEFORE FINANCE COST/INTEREST, EXCEPTIONAL, EXTRA-ORDINARY ITEMS & TAXES (PBIEET)(V-VI-VII)	645	-1271	-2370
(IX) Finance Cost			
(a) On Central Government Loans	1263	991	769
(b) On Foreign Loans	0	0	0
(c) Others	460	552	516
(d) Less Finance Cost Capitalised	81	6	0
(e) Charged to P & L Account (a+b+c -d)	1642	1537	1285
(X) PROFIT BEFORE EXCEPTIONAL & EXTRA-ORDINARY ITEMS & TAX (PBEET)(VIII-IXe)	-997	-2808	-3655
(XI) Exceptional Items	-84	-1076	0
(XII) PROFIT BEFORE EXTRA-ORDINARY ITEMS & TAX (PBET)(X-XI)	-913	-1732	-3655
(XIII) Extra-Ordinary Items	0	0	0
(XIV) PROFIT BEFORE TAX (PBT)(XII-XIII)	-913	-1732	-3655
(XV) TAX PROVISIONS	0	0	0
(XVI) NET PROFIT / LOSS FOR THE PERIOD FROM CONTINUING OPERATIONS AFTER TAX(XIV-XV)	-913	-1732	-3655
(XVII) Profit/Loss from discontinuing operations	0	0	0
(XVIII) Tax expenses of discontinuing operations	0	0	0
(XIX) Profit/Loss from discontinuing operations (after Tax)(XVII-XVIII)	0	0	0
(XX) Profit/Loss for the period (XVI+XIX)	-913	-1732	-3655
Financial Ratios			
(i) Sales : Capital Employed	95.89	51.84	22.77
(ii) Cost of Sales : Sales	119.59	170.72	353.43
(iii) Salary/Wages : Sales	25.72	62.34	133.63
(iv) Net Profit : Net Worth	-	-	-
(v) Debt : Equity	2.58	2.42	2.17
(vi) Current Ratio	0.63	0.63	0.54
(vii) Trade Recievables : Sales	29.86	31.42	43.53
(viii) Total Inventory : Sales	16.59	31.18	47.51

Bharat Immunologicals and Biologicals Corp. Ltd.

Village Chola, Bulandshahr, Uttar Pradesh – 203 203
www.bibcol.com

The Company

Bharat Immunological and Biologicals Corp. Ltd. (BIBCOL) was incorporated on 10.3.1989 with the objective to produce Oral Polio Vaccine (OPV) to support the target of the Government of India to eradicate Poliomyelitis.

BIBCOL is an uncategorized BIFR referred sick listed CPSE in Chemicals & Pharmaceuticals sector under the administrative control of Ministry of Science and Technology, Department of Biotechnology with 59.25% shareholding by the Government of India. The company employed 112 regular employees (Executives 41 & Non-Executives 71) as on 31.3.2016. Its registered and corporate offices are at Bulandshahr, Uttar Pradesh.

Vision / Mission

The vision of the company is to help India to become self-reliant in the field of Vaccines, Drugs & Pharmaceuticals by affirming values of Quality, Integrity, Innovation, Performance, Customer focus and Leadership and to emerge as a reliable, high quality, cost effective provider of Vaccines & Drugs for India's Public Health Sector.

The mission of the company is to achieve excellence in the field of production of quality vaccines, biological and health care products.

Industrial / Business Operations

The main activity of BIBCOL is to manufacture and supply of formulation of Oral Polio Vaccine (OPV) and production of Zinc Dispersible Tablet through its single operating unit at Bulandshahr, Uttar Pradesh. To add in product line, company is aiming to get the license for manufacturing of Ready to Use Therapeutic Food. Further it is also aim to diversify into Plasma derived medicines.

Performance Highlights

The physical performance of the company during the last three years is given below:

Main Product	Unit	Performance during		
		2015-16	2014-15	2013-14
OPV ZINC DMK	₹ in Lakh	12803	14622	20275

Total revenue of the company registered a decrease of ₹17.53 crore during 2015-16 which went down to ₹129.42 crore in 2015-16 from ₹146.95 crore during 2014-15. The profit of the company has also gone down by ₹7.76 crore to a loss of ₹(-) 6.21 crore in 2015-16, from ₹1.55 crore in previous year due to decrease in revenue.

Return on networth and net profit ratio of the company is negative in 2015-16. (Fig. 2). The current ratio of company is at 2.00:1 during 2015-16 as against 2.08:1 in the previous year. Balance Sheet and Profit & Loss Account of the company and selected financial ratios during the period 2013-14 to 2015-16 can be seen on the adjoining page.




Fig.1




Fig.2

Strategic issues

The key concern of the company is perpetual import of bulk vaccine of OPV, dependency on single product, and low market for zinc as relatively new product in diarrhoea management.

BHARAT IMMUNOLOGICALS & BIOLOGICALS CORP. LTD.

BALANCE SHEET	(₹ in Lakhs)		
PARTICULARS	2015-16	2014-15	2013-14
I. EQUITY & LIABILITIES			
AUTHORISED CAPITAL	5100	5100	5100
(1) Shareholders' Funds			
(a) Share Capital			
(i) Central Govt	2558	2559	2558
(ii) Others	1760	1759	1760
(b) Reserves & Surplus	-807	-186	-982
(c) Money received against share warrants	0	0	0
Total Shareholders' Funds (1(a)+1(b)+1(c))	3511	4132	3336
(2) Share application money pending allotment	0	0	0
(3) Non-current Liabilities			
(a) Long Term Borrowings	0	0	0
(b) Deferred tax liabilities (Net)	0	28	0
(c) Other Long-term liabilities	36	24	0
(d) Long-term provisions	304	308	242
Total Non-Current Liabilities 3(a) to 3(d)	340	360	242
(4) Current Liabilities			
(a) Short Term Borrowings	943	-884	0
(b) Trade Payables	770	3126	3623
(c) Other current liabilities	1261	1238	1770
(d) Short-term provisions	13	53	9
Total Current Liabilities 4(a) to 4(d)	2987	3533	5402
TOTAL EQUITY & LIABILITIES (1+2+3+4)	6838	8025	8980
II. ASSETS			
(1) Non-Current Assets			
(a) Total Gross Fixed Assets	4519	4521	4455
(ai) Accumulated Depreciation, Depletion & Amortisation	3969	3916	3722
(aii) Accumulated Impairment	0	0	0
(b) Total Net Fixed Assets ((a)-(ai)-(aii))	550	605	733
(c) Capital work in progress	22	22	22
(d) Intangible assets under developmet	0	0	0
(e) Non-Current Investments	0	0	0
(f) Deferred Tax Assets (Net)	247	0	475
(g) Long Term Loans and Advances	43	40	26
(h) Other Non-Current Assets	0	0	0
Total Non-Current Assets (b+c+d+e+f+g+h)	862	667	1256
(2) Current Assets			
(a) Current Investments	0	0	0
(b) Inventories	2247	2564	3208
(c) Trade Recievables	1308	1370	108
(d) Cash & Bank Balance	2014	3026	4135
(e) Short-term Loans & Advances	363	365	151
(f) Other Current Assets	44	33	122
Total Current Assets (a+b+c+d+e+f)	5976	7358	7724
TOTAL ASSETS (1+2)	6838	8025	8980
Important Indicators			
(i) Investment	4318	4318	4318
(ii) Capital Employed	3511	4132	3336
(iii) Net Worth	3511	4132	3336
(iv) Net Current Assets	2989	3825	2322
(v) Cost of Sales	13598	14378	16501
(vi) Net Value Added (at market price)	1088	2013	1727
(vii) Total Regular Employees (Nos.)	112	115	118
(viii) Avg. Monthly Emoluments per Employee(₹)	74628	69638	59251

PROFIT & LOSS ACCOUNT	(₹ in Lakhs)		
PARTICULARS	2015-16	2014-15	2013-14
(I) Revenue from Operations (Gross)	12803	14624	17297
Less : Excise Duty	0	2	17
Revenue from Operations (Net)	12803	14622	17280
(II) Other Income	139	73	108
(III) Total Revenue (I+II)	12942	14695	17388
(IV) Expenditure on:			
(a) Cost of materials consumed	11293	11444	15251
(b) Purchase of stock-in-trade	0	0	0
(c) Changes in inventories of finished goods, work-in-progress and stock in trade	-656	-341	-1832
(d) Stores & Spares	115	1275	182
(e) Power & Fuel	223	221	207
(f) Salary, Wages & Benefits/Employees Expense	1003	961	839
(g) Other Operating/direct/manufacturing Expenses	938	726	206
(h) Rent, Royalty & Cess	0	0	1
(i) Loss on sale of Assets/Investments	0	0	0
(j) Other Expenses	617	1	1521
Total Expenditure (IV (a to j))	13533	14287	16375
(V) PROFIT BEFORE DEPRECIATION, & IMPAIRMENT, FINANCE CHARGES/INTEREST, EXCEPTIONAL & EXTRAORDINARY ITEMS & TAXES (PBDIET)(III-IV)	-591	408	1013
(VI) Depreciation, Depletion & Amortisation	65	91	126
(VII) Impairment	0	0	0
(VIII) PROFIT BEFORE FINANCE COST/INTEREST, EXCEPTIONAL, EXTRA-ORDINARY ITEMS & TAXES (PBIET)(V-VI-VII)	-656	317	887
(IX) Finance Cost			
(a) On Central Government Loans	0	0	0
(b) On Foreign Loans	0	0	0
(c) Others	241	108	199
(d) Less Finance Cost Capitalised	0	0	0
(e) Charged to P & L Account (a+b+c -d)	241	108	199
(X) PROFIT BEFORE EXCEPTIONAL & EXTRA-ORDINARY ITEMS & TAX (PBEET)(VIII-IXe)	-897	209	688
(XI) Exceptional Items	0	0	0
(XII) PROFIT BEFORE EXTRA-ORDINARY ITEMS & TAX (PBET)(X-XI)	-897	209	688
(XIII) Extra-Ordinary Items	0	0	0
(XIV) PROFIT BEFORE TAX (PBT)(XII-XIII)	-897	209	688
(XV) TAX PROVISIONS	-276	54	186
(XVI) NET PROFIT / LOSS FOR THE PERIOD FROM CONTINUING OPERATIONS AFTER TAX(XIV-XV)	-621	155	502
(XVII) Profit/Loss from discontinuing operations	0	0	0
(XVIII) Tax expenses of discontinuing operations	0	0	0
(XIX) Profit/Loss from discontinuing operations (after Tax)(XVII-XVIII)	0	0	0
(XX) Profit/Loss for the period (XVI+XIX)	-621	155	502
Financial Ratios			
(i) Sales : Capital Employed	364.65	353.87	517.99
(ii) Cost of Sales : Sales	106.21	98.33	95.49
(iii) Salary/Wages : Sales	7.83	6.57	4.86
(iv) Net Profit : Net Worth	-17.69	3.75	15.05
(v) Debt : Equity	0	0	0
(vi) Current Ratio	2	2.08	1.43
(vii) Trade Recievables : Sales	10.22	9.37	0.62
(viii) Total Inventory : Sales	17.55	17.54	18.56

Brahmaputra Crackers & Polymer Ltd.

Hotel Brahmaputra Ashok, M.G. Road, Guwahati-781001
www.bcplonline.co.in

The Company

Brahmaputra Crackers & Polymer Ltd (BCPL), a joint venture company, was incorporated on 08.01.2007 as Central Public Sector Enterprise under Department of Chemicals & Petrochemicals. GAIL (India) Limited is the main promoter of BCPL having 70% of equity participation and the remaining 30% equity is equally shared by Oil India Ltd (OIL), Numaligarh Refinery Limited (NRL) and Government of Assam.

BCPL is a schedule 'B' CPSE in Chemicals & Petrochemicals sector under the administrative control of the Ministry of Chemicals & Fertilizers, D/o Chemicals & Petro Chemicals, Govt. of India. The company employed 579 regular employees (Executives 579 & Non-Executives 0) as on 31.3.2016. Its registered and corporate office are at New Delhi.

Vision / Mission

The vision of the company is to emerge as a dominant petrochemical player in the north east region, providing value to stakeholders, offering best in class products & services, contributing to economic growth while remaining environmentally conscious.

The mission of the company is to established significant presence in the north-east region in petrochemical sector by way of production/sourcing and marketing of quality products, deploying efficient distribution and marketing channels to cater to the needs of target customers.

Industrial / Business Operations

BCPL is producing petrochemical products from the raw materials received from OIL and NRL. Raw materials in the form of Natural Gas and Naptha are supplied by OIL and NRL respectively. The end products of the Complex are High Density Polyethylene (HDPE) and Linear Low Density polyethylene (LLDPE) totalling 2,20,000 Tonnes per Annum (TPA) and 60,000 TPA of Polypropylene (PP). The other products include Hydrogenated Pyrolysis Gasoline and Fuel oil. The main complex of BCPL is located at Lepetkata, Dist.-Dibrugarh, Assam. BCPL has processing facilities at Duliajan in Dibrugarh District and Lakwa in Sivasagar District. The Project was commissioned on 2nd January, 2016 and dedicated to the Nation on 5th Feb.

The products are being marketed by GAIL through a chain of Stockists and Retailers. BCPL products are marketed to business entities engaged in the business of manufacturing plastic goods.

Performance Highlights

During the year 2015-16, the company earned at total revenue of ₹49.51 crore and reported a loss of ₹(-) 270.23 crore.

The current ratio of company is at 0.42:1 during 2015-16 as against 0.39:1 in the previous year. Balance Sheet and Profit & Loss Account of the company and selected financial ratios during the period 2015-16 can be seen on the adjoining page.

Strategic Issues

Socio economic development of north-east region.

BRAHAMPUTRA CRACKERS & POLYMER LTD.

BALANCE SHEET	₹ in Lakhs		
PARTICULARS	2015-16	2014-15	2013-14
I. EQUITY & LIABILITIES			
AUTHORISED CAPITAL	200000	200000	200000
(1) Shareholders' Funds			
(a) Share Capital			
(i) Central Govt	0	0	0
(ii) Others	117371	117371	113287
(b) Reserves & Surplus	437016	468892	468892
(c) Money received against share warrants	0	0	0
Total Shareholders' Funds (1(a)+1(b)+1(c))	554387	586263	582179
(2) Share application money pending allotment	0	0	4084
(3) Non-current Liabilities			
(a) Long Term Borrowings	281343	212337	123917
(b) Deferred tax liabilities (Net)	750	0	0
(c) Other Long-term liabilities	0	0	0
(d) Long-term provisions	271	190	104
Total Non-Current Liabilities 3(a) to 3(d)	282364	212527	124021
(4) Current Liabilities			
(a) Short Term Borrowings	18033	0	0
(b) Trade Payables	12685	0	0
(c) Other current liabilities	52889	43798	38625
(d) Short-term provisions	44058	31329	29094
Total Current Liabilities 4(a) to 4(d)	127665	75127	67719
TOTAL EQUITY & LIABILITIES (1+2+3+4)	964416	873917	778003
II. ASSETS			
(1) Non-Current Assets			
(a) Total Gross Fixed Assets	839709	32003	27142
(ai) Accumulated Depreciation, Depletion & Amortisation	14276	4283	2988
(aii) Accumulated Impairment	0	0	0
(b) Total Net Fixed Assets ((a)-(ai)-(aii))	825433	27720	24154
(c) Capital work in progress	38613	566989	559005
(d) Intangible assets under developmet	0	0	0
(e) Non-Current Investments	0	0	0
(f) Deferred Tax Assets (Net)	0	0	0
(g) Long Term Loans and Advances	46603	248873	162021
(h) Other Non-Current Assets	762	674	426
Total Non-Current Assets (b+c+d+e+f+g+h)	911411	844256	745606
(2) Current Assets			
(a) Current Investments	0	0	0
(b) Inventories	27585	0	0
(c) Trade Recievables	55	0	0
(d) Cash & Bank Balance	2612	11020	5885
(e) Short-term Loans & Advances	1288	2761	9070
(f) Other Current Assets	21465	15880	17442
Total Current Assets (a+b+c+d+e+f)	53005	29661	32397
TOTAL ASSETS (1+2)	964416	873917	778003
Important Indicators			
(i) Investment	398714	329708	241288
(ii) Capital Employed	835730	798600	710180
(iii) Net Worth	554387	586263	586263
(iv) Net Current Assets	-74660	-45466	-35322
(v) Cost of Sales	24427	0	0
(vi) Net Value Added (at market price)	-8258	5177	-94715
(vii) Total Regular Employees (Nos.)	579	430	353
(viii) Avg. Monthly Emoluments per Employee(₹)	30081	0	0

PROFIT & LOSS ACCOUNT	₹ in Lakhs		
PARTICULARS	2015-16	2014-15	2013-14
(I) Revenue from Operations (Gross)	192	0	0
Less : Excise Duty	23	0	0
Revenue from Operations (Net)	169	0	0
(II) Other Income	4782	0	0
(III) Total Revenue (I+II)	4951	0	0
(IV) Expenditure on:			
(a) Cost of materials consumed	13575	0	0
(b) Purchase of stock-in-trade	0	0	0
(c) Changes in inventories of finished goods, work-in-progress and stock in trade	-3097	0	0
(d) Stores & Spares	0	0	0
(e) Power & Fuel	220	0	0
(f) Salary, Wages & Benefits/Employees Expense	2090	0	0
(g) Other Operating/direct/manufacturing Expenses	2574	0	0
(h) Rent, Royalty & Cess	26	0	0
(i) Loss on sale of Assets/Investments	0	0	0
(j) Other Expenses	668	0	0
Total Expenditure (IV (a to j))	16056	0	0
(V) PROFIT BEFORE DEPRECIATION, & IMPAIRMENT, FINANCE CHARGES/INTEREST, EXCEPTIONAL & EXTRAORDINARY ITEMS & TAXES (PBDIET)(III-IV)	-11105	0	0
(VI) Depreciation, Depletion & Amortisation	8371	0	0
(VII) Impairment	0	0	0
(VIII) PROFIT BEFORE FINANCE COST/INTEREST, EXCEPTIONAL, EXTRA-ORDINARY ITEMS & TAXES (PBIET)(V-VI-VII)	-19476	0	0
(IX) Finance Cost			
(a) On Central Government Loans	0	0	0
(b) On Foreign Loans	0	0	0
(c) Others	24707	0	0
(d) Less Finance Cost Capitalised	17909	0	0
(e) Charged to P & L Account (a+b+c -d)	6798	0	0
(X) PROFIT BEFORE EXCEPTIONAL & EXTRA-ORDINARY ITEMS & TAX (PBEET)(VIII-IXe)	-26274	0	0
(XI) Exceptional Items	0	0	0
(XII) PROFIT BEFORE EXTRA-ORDINARY ITEMS & TAX (PBET)(X-XI)	-26274	0	0
(XIII) Extra-Ordinary Items	0	0	0
(XIV) PROFIT BEFORE TAX (PBT)(XII-XIII)	-26274	0	0
(XV) TAX PROVISIONS	749	0	0
(XVI) NET PROFIT / LOSS FOR THE PERIOD FROM CONTINUING OPERATIONS AFTER TAX(XIV-XV)	-27023	0	0
(XVII) Profit/Loss from discontinuing operations	0	0	0
(XVIII) Tax expenses of discontinuing operations	0	0	0
(XIX) Profit/Loss from discontinuing operations (after Tax)(XVII-XVIII)	0	0	0
(XX) Profit/Loss for the period (XVI+XIX)	-27023	0	0
Financial Ratios			
(i) Sales : Capital Employed	0.02	0	0
(ii) Cost of Sales : Sales	14453.85	0	0
(iii) Salary/Wages : Sales	1236.69	0	0
(iv) Net Profit : Net Worth	-4.87	0	0
(v) Debt : Equity	2.4	1.81	1.06
(vi) Current Ratio	0.42	0.39	0.48
(vii) Trade Recievables : Sales	32.54	0	0
(viii) Total Inventory : Sales	16322.49	0	0

Goa Antibiotics and Pharmaceuticals Ltd.

Tuem Pernem, Goa
www.gaplgoa.com

The Company

Goa Antibiotics & Pharmaceuticals Limited (GAPL) is a subsidiary of HLL Lifecare Limited was incorporated on 09.12.1980 under Companies Act, 1956 as a joint Venture between Hindustan Antibiotics Limited (HAL), Pune with 51% stake and EDC Limited, a Government of Goa Undertaking. The share holdings of HAL in GAPL were transferred in favour of EDC Limited in the year 1987, with the consent of Government of India. HLL Lifecare Limited is having major stake of GAPL, acquiring 74% stake on 19th March 2014 and the balance 26% stake is with Government of Goa.

GAPL is an uncategorised CPSE in Chemicals & Pharmaceuticals Sector under administrative control of Ministry of Health & Family Welfare; Government of India. The Company employed 194 regular employees (Executives-79 & Non-Executives-115) as on 31.3.2016. Its registered office are at Goa.

Mission/Vision

The mission/vision of the company is to create a healthier and happier world, emerge as a leading pharma public sector organization by 2020, and cater to the general public healthcare domain by setting benchmarks for excellence in Innovation, product quality, customer satisfaction, value creation and sustained growth.

Industrial / Business Operations

GAPL is engaged in manufacturing and supply of Allopathic Medicine manufacture at its unit at TuemPernem Goa. Besides company is having lease facility at Ajmer and Jaipur in the state of Rajasthan for manufacturing of Ayurvedic and Homeopathic medicines respectively. The company also runs a chain of 24 X 7 retail pharmacy outlets in the State of Goa at Goa Medical College Bambolim and Hospicio Hospital Margao. The product range of the company comprises of 338 products of allopathic formulation through its operation unit at Tuem.

Performance Highlights

The physical performance of the company during the last three years is given below:

Main Products / Services	Unit	Performance during		
		2015-16	2014-15	2013-14
Tablet	Lakh No.	1728	1543	1750
Capsules	Lakh No.	249	1478	438
Vials	Lakh No.	68	41	47
Syrup	Lakh Liter	8.87	10	12

Total revenue of the company registered an increase of ₹0.66 crore during 2015-16, which went up to ₹48.99 crore in 2015-16 from ₹48.33 crore in 2014-15. The profit of the company increased to ₹2.30 crore in 2015-16 from ₹1.80 crore in 2014-15.

Return on net worth of the company is decreased to 36.80% in 2015-16 from 53.73% in 2014-15. Net profit ratio of the company is 4.71% in 2015-16 from 3.78% in 2014-15.

The current ratio of company is at 1.28:1 during 2015-16 same as 1.28:1 in the previous year. Balance Sheet and Profit & Loss Account of the company and selected financial ratios during the financial year 2013-14 to 2015-16 can be seen on the adjoining page.




Fig (1)




Fig (2)

Strategic issue

Company is inducting innovative formulations in allopathic range regularly and thus enabled GAPL to reach larger section of the population. Manufacturing facilities are upgraded to encompass latest technology in the field to sustain competitive edge. GAPL is looking forward to promote chain of retail medical stores at strategic locations to ensure prompt availability of life saving medicines to the needy round -the -clock.

GOA ANTIBIOTICS & PHARMACEUTICALS LTD.

BALANCE SHEET	(₹ in Lakhs)		
PARTICULARS	2015-16	2014-15	2013-14
I. EQUITY & LIABILITIES			
AUTHORISED CAPITAL	2500	2500	2500
(1) Shareholders' Funds			
(a) Share Capital			
(i) Central Govt	1407	1407	1407
(ii) Others	495	495	495
(b) Reserves & Surplus	-1277	-1567	-1747
(c) Money received against share warrants	0	0	0
Total Shareholders' Funds (1(a)+1(b)+1(c))	625	335	155
(2) Share application money pending allotment	0	0	0
(3) Non-current Liabilities			
(a) Long Term Borrowings	512	676	859
(b) Deferred tax liabilities (Net)	0	0	0
(c) Other Long-term liabilities	18	0	0
(d) Long-term provisions	0	0	0
Total Non-Current Liabilities 3(a) to 3(d)	530	676	859
(4) Current Liabilities			
(a) Short Term Borrowings	31	0	0
(b) Trade Payables	1559	1518	1177
(c) Other current liabilities	444	300	237
(d) Short-term provisions	230	350	40
Total Current Liabilities 4(a) to 4(d)	2264	2168	1454
TOTAL EQUITY & LIABILITIES (1+2+3+4)	3419	3179	2468
II. ASSETS			
(1) Non-Current Assets			
(a) Total Gross Fixed Assets	950	942	962
(ai) Accumulated Depreciation, Depletion & Amortisation	565	554	509
(aii) Accumulated Impairment	0	0	0
(b) Total Net Fixed Assets ((a)-(ai)-(aii))	385	388	453
(c) Capital work in progress	0	0	0
(d) Intangible assets under developmet	37	0	0
(e) Non-Current Investments	0	0	0
(f) Deferred Tax Assets (Net)	82	0	0
(g) Long Term Loans and Advances	28	19	5
(h) Other Non-Current Assets	0	0	0
Total Non-Current Assets (b+c+d+e+f+g+h)	532	407	458
(2) Current Assets			
(a) Current Investments	0	0	0
(b) Inventories	280	128	116
(c) Trade Recievables	2391	2200	1487
(d) Cash & Bank Balance	52	384	325
(e) Short-term Loans & Advances	137	50	25
(f) Other Current Assets	27	10	57
Total Current Assets (a+b+c+d+e+f)	2887	2772	2010
TOTAL ASSETS (1+2)	3419	3179	2468
Important Indicators			
(i) Investment	2414	2578	2761
(ii) Capital Employed	1137	1011	1014
(iii) Net Worth	625	335	155
(iv) Net Current Assets	623	604	556
(v) Cost of Sales	4434	4351	3647
(vi) Net Value Added (at market price)	1561	1051	1291
(vii) Total Regular Employees (Nos.)	194	199	207
(viii) Avg. Monthly Emoluments per Employee(₹)	41538	32998	27053

PROFIT & LOSS ACCOUNT	(₹ in Lakhs)		
PARTICULARS	2015-16	2014-15	2013-14
(I) Revenue from Operations (Gross)	5059	4943	4059
Less : Excise Duty	172	176	131
Revenue from Operations (Net)	4887	4767	3928
(II) Other Income	12	66	14
(III) Total Revenue (I+II)	4899	4833	3942
(IV) Expenditure on:			
(a) Cost of materials consumed	1396	1492	1325
(b) Purchase of stock-in-trade	1153	1189	741
(c) Changes in inventories of finished goods, work-in-progress and stock in trade	-36	-14	197
(d) Stores & Spares	13	22	14
(e) Power & Fuel	112	126	109
(f) Salary, Wages & Benefits/Employees Expense	967	788	672
(g) Other Operating/direct/manufacturing Expenses	386	462	533
(h) Rent, Royalty & Cess	34	3	0
(i) Loss on sale of Assets/Investments	0	0	0
(j) Other Expenses	364	232	0
Total Expenditure (IV (a to j))	4389	4300	3591
(V) PROFIT BEFORE DEPRECIATION, & IMPAIRMENT, FINANCE CHARGES/INTEREST, EXCEPTIONAL & EXTRAORDINARY ITEMS & TAXES (PBDIET)(III-IV)	510	533	351
(VI) Depreciation, Depletion & Amortisation	45	51	56
(VII) Impairment	0	0	0
(VIII) PROFIT BEFORE FINANCE COST/INTEREST, EXCEPTIONAL, EXTRA-ORDINARY ITEMS & TAXES (PBIEET)(V-VI-VII)	465	482	295
(IX) Finance Cost			
(a) On Central Government Loans	0	0	0
(b) On Foreign Loans	0	0	0
(c) Others	47	77	47
(d) Less Finance Cost Capitalised	0	0	0
(e) Charged to P & L Account (a+b+c -d)	47	77	47
(X) PROFIT BEFORE EXCEPTIONAL & EXTRA-ORDINARY ITEMS & TAX (PBEET)(VIII-IXe)	418	405	248
(XI) Exceptional Items	103	223	-61
(XII) PROFIT BEFORE EXTRA-ORDINARY ITEMS & TAX (PBET)(X-XI)	315	182	309
(XIII) Extra-Ordinary Items	0	0	10
(XIV) PROFIT BEFORE TAX (PBT)(XII-XIII)	315	182	299
(XV) TAX PROVISIONS	85	2	0
(XVI) NET PROFIT / LOSS FOR THE PERIOD FROM CONTINUING OPERATIONS AFTER TAX(XIV-XV)	230	180	299
(XVII) Profit/Loss from discontinuing operations	0	0	0
(XVIII) Tax expenses of discontinuing operations	0	0	0
(XIX) Profit/Loss from discontinuing operations (after Tax)(XVII-XVIII)	0	0	0
(XX) Profit/Loss for the period (XVI+XIX)	230	180	299
Financial Ratios			
(i) Sales : Capital Employed	429.82	471.51	387.38
(ii) Cost of Sales : Sales	90.73	91.27	92.85
(iii) Salary/Wages : Sales	19.79	16.53	17.11
(iv) Net Profit : Net Worth	36.8	53.73	192.9
(v) Debt : Equity	0.27	0.36	0.45
(vi) Current Ratio	1.28	1.28	1.38
(vii) Trade Recievables : Sales	48.93	46.15	37.86
(viii) Total Inventory : Sales	5.73	2.69	2.95

Hindustan Antibiotics Ltd.

Pimpri, Pune-411018
www.hindantibiotics.gov.in

The Company

Hindustan Antibiotics Ltd. (HAL) was incorporated in 1954 with the objective of manufacturing and marketing of life saving bulk drugs at affordable prices through network of Government Hospitals. The company has diversified into production of agriculture & veterinary products.

HAL is a schedule 'C' / BIFR referred CPSE in Chemicals & Pharmaceuticals sector under the administrative control of M/o Chemicals and Fertilizers, D/o Pharmaceuticals with 100% shareholding by the Government of India. The company employed 1025 regular employees (Executives 226 & Non-Executives 799) as on 31.3.2016. Its registered and corporate offices are at Pune, Maharashtra.

Vision / Mission

The vision of the company is to focus on selected range of products after revamping the product mix as per the market requirements and introduce newer products in the market as a part of the short term, medium term and long term planning, taking into consideration the company's strength.

The mission of the company is to make life saving drugs available to the common people of the country.

Industrial / Business Operations

HAL is engaged in manufacturing and marketing of life saving drugs through its single operating unit at Pune, Maharashtra. The total number of products manufactured by the company is 70. These are distributed in three segments namely Bulk, Formulation and others.

The company has two subsidiaries, namely Maharashtra Antibiotics & Pharmaceuticals Ltd. (MAPL) and Karnataka Antibiotics & Pharmaceuticals Ltd.

Performance Highlights

The physical performance of the company for last three years is given below:

Main Products	Unit	Performance during		
		2015-16	2014-15	2013-14
Formulations	No.in Lakhs	1181	1783	2902

Total revenue of the company registered a reduction of

₹9.69 crore during 2015-16, which went down to ₹14.94 crore in 2015-16 from ₹24.63 crore in 2014-15 (Fig.1). The loss of the company has also gone up by ₹6.63 crore to ₹(-) 77.18 crore in 2015-16, from ₹(-) 70.55 crore in previous year mainly due to decrease in the sales turnover.

Net worth of the company is negative. The current ratio of company is at 0.38:1 during 2015-16 as against 0.3:1 in the previous year. Balance Sheet and Profit & Loss Account of the company and selected financial ratios during the period 2013-14 to 2015-16 can be seen on the adjoining page.




Fig.1

Strategic issues

Despite three capital restructuring schemes in 1983, 1988 and 1994, the company became sick in 1997. Government of India approved the 4th Rehabilitation Scheme on the basis of the recommendations of BRPSE on 9.3.2006 with a cash assistance of ₹137.59 crore and non-cash assistance of ₹267.57 crore. The company started implementation of the Rehabilitation Scheme sanctioned by BIFR vide its order dated 05.06.2007. The projects included in the Rehabilitation scheme have been forwarded to administrative Ministry. Between 2007-08 and 2010-11 company has received ₹37.17 crore for new projects. HAL as a strategy is focusing on increasing Trade sale and adopted Business Associate / Pharma Sales Executive (BAPSE) model to enhance the trade sale.

HINDUSTAN ANTIBIOTICS LTD.

BALANCE SHEET	(₹ in Lakhs)		
PARTICULARS	2015-16	2014-15	2013-14
I. EQUITY & LIABILITIES			
AUTHORISED CAPITAL	10000	10000	10000
(1) Shareholders' Funds			
(a) Share Capital			
(i) Central Govt	7172	7172	7172
(ii) Others	0	0	0
(b) Reserves & Surplus	-57087	-52911	-43517
(c) Money received against share warrants	0	0	0
Total Shareholders' Funds (1(a)+1(b)+1(c))	-49915	-45739	-36345
(2) Share application money pending allotment	0	0	0
(3) Non-current Liabilities			
(a) Long Term Borrowings	29751	14710	16251
(b) Deferred tax liabilities (Net)	0	0	0
(c) Other Long-term liabilities	0	0	0
(d) Long-term provisions	5029	4429	3615
Total Non-Current Liabilities 3(a) to 3(d)	34780	19139	19866
(4) Current Liabilities			
(a) Short Term Borrowings	16155	14976	14389
(b) Trade Payables	3009	3279	3549
(c) Other current liabilities	11974	27652	17984
(d) Short-term provisions	2564	64	58
Total Current Liabilities 4(a) to 4(d)	33702	45971	35980
TOTAL EQUITY & LIABILITIES (1+2+3+4)	18567	19371	19501
II. ASSETS			
(1) Non-Current Assets			
(a) Total Gross Fixed Assets	21891	21869	21720
(ai) Accumulated Depreciation, Depletion & Amortisation	16830	16516	15743
(aii) Accumulated Impairment	0	0	0
(b) Total Net Fixed Assets ((a)-(ai)-(aii))	5061	5353	5977
(c) Capital work in progress	644	372	460
(d) Intangible assets under developmet	0	0	0
(e) Non-Current Investments	0	0	0
(f) Deferred Tax Assets (Net)	0	0	0
(g) Long Term Loans and Advances	0	0	0
(h) Other Non-Current Assets	0	0	0
Total Non-Current Assets (b+c+d+e+f+g+h)	5705	5725	6437
(2) Current Assets			
(a) Current Investments	0	0	0
(b) Inventories	569	742	942
(c) Trade Recievables	251	472	482
(d) Cash & Bank Balance	1493	1708	1165
(e) Short-term Loans & Advances	9448	9619	9447
(f) Other Current Assets	1101	1105	1028
Total Current Assets (a+b+c+d+e+f)	12862	13646	13064
TOTAL ASSETS (1+2)	18567	19371	19501
Important Indicators			
(i) Investment	36923	21882	23423
(ii) Capital Employed	-20164	-31029	-20094
(iii) Net Worth	-49915	-45739	-36345
(iv) Net Current Assets	-20840	-32325	-22916
(v) Cost of Sales	7060	7369	8212
(vi) Net Value Added (at market price)	-408	274	-355
(vii) Total Regular Employees (Nos.)	1025	1051	1120
(viii) Avg. Monthly Emoluments per Employee(₹)	39642	38796	33624
2015-16 PROVISIONAL			

PROFIT & LOSS ACCOUNT	(₹ in Lakhs)		
PARTICULARS	2015-16	2014-15	2013-14
(I) Revenue from Operations (Gross)	1512	1854	3019
Less : Excise Duty	217	238	280
Revenue from Operations (Net)	1295	1616	2739
(II) Other Income	199	847	277
(III) Total Revenue (I+II)	1494	2463	3016
(IV) Expenditure on:			
(a) Cost of materials consumed	660	754	1361
(b) Purchase of stock-in-trade	0	0	0
(c) Changes in inventories of finished goods, work-in-progress and stock in trade	115	76	163
(d) Stores & Spares	49	46	72
(e) Power & Fuel	316	328	567
(f) Salary, Wages & Benefits/Employees Expense	4876	4893	4519
(g) Other Operating/direct/manufacturing Expenses	568	744	887
(h) Rent, Royalty & Cess	0	10	16
(i) Loss on sale of Assets/Investments	0	0	0
(j) Other Expenses	162	107	150
Total Expenditure (IV (a to j))	6746	6958	7735
(V) PROFIT BEFORE DEPRECIATION, & IMPAIRMENT, FINANCE CHARGES/INTEREST, EXCEPTIONAL & EXTRAORDINARY ITEMS & TAXES (PBDIET)(III-IV)	-5252	-4495	-4719
(VI) Depreciation, Depletion & Amortisation	314	411	477
(VII) Impairment	0	0	0
(VIII) PROFIT BEFORE FINANCE COST/INTEREST, EXCEPTIONAL, EXTRA-ORDINARY ITEMS & TAXES (PBIEET)(V-VI-VII)	-5566	-4906	-5196
(IX) Finance Cost			
(a) On Central Government Loans	1098	784	555
(b) On Foreign Loans	0	0	0
(c) Others	1054	1365	2672
(d) Less Finance Cost Capitalised	0	0	0
(e) Charged to P & L Account (a+b+c -d)	2152	2149	3227
(X) PROFIT BEFORE EXCEPTIONAL & EXTRA-ORDINARY ITEMS & TAX (PBEET)(VIII-Xe)	-7718	-7055	-8423
(XI) Exceptional Items	0	0	0
(XII) PROFIT BEFORE EXTRA-ORDINARY ITEMS & TAX (PBET)(X-XI)	-7718	-7055	-8423
(XIII) Extra-Ordinary Items	0	0	0
(XIV) PROFIT BEFORE TAX (PBT)(XII-XIII)	-7718	-7055	-8423
(XV) TAX PROVISIONS	0	0	0
(XVI) NET PROFIT / LOSS FOR THE PERIOD FROM CONTINUING OPERATIONS AFTER TAX(XIV-XV)	-7718	-7055	-8423
(XVII) Profit/Loss from discontinuing operations	0	0	0
(XVIII) Tax expenses of discontinuing operations	0	0	0
(XIX) Profit/Loss from discontinuing operations (after Tax)(XVII-XVIII)	0	0	0
(XX) Profit/Loss for the period (XVI+XIX)	-7718	-7055	-8423
Financial Ratios			
(i) Sales : Capital Employed	-6.42	-5.21	-13.63
(ii) Cost of Sales : Sales	545.17	456	299.82
(iii) Salary/Wages : Sales	376.53	302.78	164.99
(iv) Net Profit : Net Worth	-	-	-
(v) Debt : Equity	4.15	2.05	2.27
(vi) Current Ratio	0.38	0.3	0.36
(vii) Trade Recievables : Sales	19.38	29.21	17.6
(viii) Total Inventory : Sales	43.94	45.92	34.39

Hindustan Fluorocarbons Ltd.

303,3rd Floor, Babukhan Estate Basheerbagh, Hyderabad, - 500 001
www.hfl.co.in

The Company

Hindustan Fluorocarbons Ltd. (HFCL) was incorporated on 14.07.1983 (commencement of business in 1988) with the objective to manufacture various grades of Poly Tetra Fluor Ethylene (PTFE) as import substitute and to save foreign exchange. The company is a subsidiary of Hindustan Organic Chemicals Ltd. (HOCL), which holds 56.43% equity of HFCL. The other joint venture partner is the Government of Andhra Pradesh through Andhra Pradesh Industrial Development Corp. (APIDC) having 4.44% equity in the company.

HFCL is a schedule 'D' listed BIFR referred CPSE in Chemicals & Pharmaceuticals sector under the administrative control of M/o Chemicals and Fertilizers, D/o Chemicals and Petrochemicals. The company employed 141 regular employees (Executives 94 and Non-executives 47) as on 31.3.2016. HFCL's registered and corporate offices are at Hyderabad.

Mission/Vision

The mission/vision of the company is to position itself to be a niche player in the production of fluorospeciality chemicals and advanced grades of PTFE.

Industrial / Business Operations

HFCL is engaged in production and marketing of products PTFE (Poly Tetra Fluoro Ethylene), CFM-22 (Chloro Fluoro Methane Gas (R-22)), and TFE (Tetra Fluoro Ethylene). HFCL has a manufacturing unit at, Medak District, Telangana State. PTFE is a versatile engineering plastic and CFM-22(R-22) is mainly used as refrigerant gas.

Performance Highlights

The average capacity utilization for all the products / services of the company was 96% during 2015-16 as against 88% in the previous year. The physical performance of the company during the last three years is given below:

Main Products	Activity	Unit	Performance during		
			2015-16	2014-15	2013-14
PTFE	Production	MT	41	106	182
CFM-22	Sales	MT	1116	727	555

Total revenue of the company registered an increase of ₹6.18 crore during 2015-16, which went up to ₹35.88 crore in 2015-16 from ₹29.70 crore in 2014-15 (Fig.1). The company has incurred a loss of ₹(-)11.11 crore in 2015-16 as against the loss of ₹(-) 3.77 crore in previous year.

Net worth of the company is negative. Net profit ratio of the company was also down to ₹(-) 30.96% in 2015-16 from ₹(-)12.69% in 2014-15. The current ratio of company was 0.15:1 during 2015-16 as against 0.34:1 in the previous year. Balance Sheet and Profit & Loss Account of the company and selected financial ratios during the period 2013-14 to 2015-16 can be seen on the adjoining page.




Fig (1)

Strategic issue

Main product of the company is PTFE. Variable cost is high as compared to the competitors. This is mainly because of uneconomical plant size and old technology. To overcome this problem, strategic decision has been taken to focus more on development of Fluoro Speciality Chemicals and advanced grades of PTFE. Accordingly, company is augmenting all efforts to develop Fluoro Speciality chemicals along with advanced grades of PTFE.

HINDUSTAN FLUOROCARBONS LIMITED

BALANCE SHEET	(₹ in Lakhs)		
PARTICULARS	2015-16	2014-15	2013-14
I. EQUITY & LIABILITIES			
AUTHORISED CAPITAL	2100	2100	2100
(1) Shareholders' Funds			
(a) Share Capital			
(i) Central Govt	0	0	0
(ii) Others	1961	1961	1961
(b) Reserves & Surplus	-8328	-7217	-6812
(c) Money received against share warrants	0	0	0
Total Shareholders' Funds (1(a)+1(b)+1(c))	-6367	-5256	-4851
(2) Share application money pending allotment	0	0	0
(3) Non-current Liabilities			
(a) Long Term Borrowings	1028	2033	936
(b) Deferred tax liabilities (Net)	0	0	0
(c) Other Long-term liabilities	0	0	0
(d) Long-term provisions	636	483	405
Total Non-Current Liabilities 3(a) to 3(d)	1664	2516	1341
(4) Current Liabilities			
(a) Short Term Borrowings	447	473	509
(b) Trade Payables	436	516	398
(c) Other current liabilities	7106	6019	5249
(d) Short-term provisions	546	478	449
Total Current Liabilities 4(a) to 4(d)	8535	7486	6605
TOTAL EQUITY & LIABILITIES (1+2+3+4)	3832	4746	3095
II. ASSETS			
(1) Non-Current Assets			
(a) Total Gross Fixed Assets	8076	7572	7161
(ai) Accumulated Depreciation, Depletion & Amortisation	5651	5514	5377
(aii) Accumulated Impairment	0	0	0
(b) Total Net Fixed Assets ((a)-(ai)-(aii))	2425	2058	1784
(c) Capital work in progress	0	62	122
(d) Intangible assets under developmet	9	0	0
(e) Non-Current Investments	0	0	0
(f) Deferred Tax Assets (Net)	0	0	0
(g) Long Term Loans and Advances	99	99	99
(h) Other Non-Current Assets	0	0	0
Total Non-Current Assets (b+c+d+e+f+g+h)	2533	2219	2005
(2) Current Assets			
(a) Current Investments	0	0	0
(b) Inventories	741	932	697
(c) Trade Recievables	229	299	275
(d) Cash & Bank Balance	241	1124	45
(e) Short-term Loans & Advances	88	172	73
(f) Other Current Assets	0	0	0
Total Current Assets (a+b+c+d+e+f)	1299	2527	1090
TOTAL ASSETS (1+2)	3832	4746	3095
Important Indicators			
(i) Investment	2989	3994	2897
(ii) Capital Employed	-5339	-3223	-3915
(iii) Net Worth	-6367	-5256	-4851
(iv) Net Current Assets	-7236	-4959	-5515
(v) Cost of Sales	4354	3828	5164
(vi) Net Value Added (at market price)	1277	1699	536
(vii) Total Regular Employees (Nos.)	141	151	179
(viii) Avg. Monthly Emoluments per Employee(₹)	82506	73620	112430

PROFIT & LOSS ACCOUNT	(₹ in Lakhs)		
PARTICULARS	2015-16	2014-15	2013-14
(I) Revenue from Operations (Gross)	3963	3275	3134
Less : Excise Duty	436	360	345
Revenue from Operations (Net)	3527	2915	2789
(II) Other Income	61	55	37
(III) Total Revenue (I+II)	3588	2970	2826
(IV) Expenditure on:			
(a) Cost of materials consumed	1701	1531	1138
(b) Purchase of stock-in-trade	0	0	0
(c) Changes in inventories of finished goods, work-in-progress and stock in trade	251	-195	352
(d) Stores & Spares	111	69	45
(e) Power & Fuel	309	506	726
(f) Salary, Wages & Benefits/Employees Expense	1396	1334	2415
(g) Other Operating/direct/manufacturing Expenses	157	347	232
(h) Rent, Royalty & Cess	20	19	19
(i) Loss on sale of Assets/Investments	0	0	0
(j) Other Expenses	272	107	122
Total Expenditure (IV (a to j))	4217	3718	5049
(V) PROFIT BEFORE DEPRECIATION, & IMPAIRMENT, FINANCE CHARGES/INTEREST, EXCEPTIONAL & EXTRAORDINARY ITEMS & TAXES (PBDIET)(III-IV)	-629	-748	-2223
(VI) Depreciation, Depletion & Amortisation	137	110	115
(VII) Impairment	0	0	0
(VIII) PROFIT BEFORE FINANCE COST/INTEREST, EXCEPTIONAL, EXTRA-ORDINARY ITEMS & TAXES (PBIET)(V-VI-VII)	-766	-858	-2338
(IX) Finance Cost			
(a) On Central Government Loans	0	0	0
(b) On Foreign Loans	0	0	0
(c) Others	345	210	144
(d) Less Finance Cost Capitalised	0	0	0
(e) Charged to P & L Account (a+b+c -d)	345	210	144
(X) PROFIT BEFORE EXCEPTIONAL & EXTRA-ORDINARY ITEMS & TAX (PBEET)(VIII-IXe)	-1111	-1068	-2482
(XI) Exceptional Items	0	-691	0
(XII) PROFIT BEFORE EXTRA-ORDINARY ITEMS & TAX (PBET)(X-XI)	-1111	-377	-2482
(XIII) Extra-Ordinary Items	0	0	0
(XIV) PROFIT BEFORE TAX (PBT)(XII-XIII)	-1111	-377	-2482
(XV) TAX PROVISIONS	0	0	0
(XVI) NET PROFIT / LOSS FOR THE PERIOD FROM CONTINUING OPERATIONS AFTER TAX(XIV-XV)	-1111	-377	-2482
(XVII) Profit/Loss from discontinuing operations	0	0	0
(XVIII) Tax expenses of discontinuing operations	0	0	0
(XIX) Profit/Loss from discontinuing operations (after Tax)(XVII-XVIII)	0	0	0
(XX) Profit/Loss for the period (XVI+XIX)	-1111	-377	-2482
Financial Ratios			
(i) Sales : Capital Employed	-66.06	-90.44	-71.24
(ii) Cost of Sales : Sales	123.45	131.32	185.16
(iii) Salary/Wages : Sales	39.58	45.76	86.59
(iv) Net Profit : Net Worth	-	-	-
(v) Debt : Equity	0.52	1.04	0.48
(vi) Current Ratio	0.15	0.34	0.17
(vii) Trade Recievables : Sales	6.49	10.26	9.86
(viii) Total Inventory : Sales	21.01	31.97	24.99

Hindustan Insecticides Limited

Scope Complex, Core-6, 2nd Floor, 7 Lodi Road, New Delhi-110003
www.hil.gov.in

The Company

Hindustan Insecticides Limited (HIL) was incorporated in 1954 with the objective to manufacture DDT and its formulations for meeting the demand of National Malaria Eradication Programme (NMEP). The current objective of the Company is to provide quality insecticides and pesticides at reasonable prices for public health and agricultural purposes and earn reasonable return.

HIL is a schedule 'C' / BIFR referred CPSE in Chemical & Pharmaceuticals sector under the administrative control of M/o Chemicals and Fertilizers, D/o Chemicals and Petrochemicals with 100% shareholding by the Government of India. The company employed 1115 regular employees (Executives 296 and Non-executives 819) as on 31.3.2016. Its registered and corporate offices are at New Delhi.

Vision / Mission

The vision of the company is to be a leading player in the field of public health & crop protection.

The mission of the company is to provide quality products at a reasonable price to the farming community for crop protection and manufacturing public health insecticides primarily for disease vector control.

Industrial / Business Operations

The product / service range comprises of technical products such as Endosulfan, Dicofof, Malathion, Butachlor, DDVP etc. and 64 agro formulations at its plants at Udyogamandal (near Cochin, Kerala), Rasayani (Maharashtra) and Bhatinda (Punjab). The company also has a well equipped central R&D complex at UdyogVihar, Gurgaon, Haryana along with an experimental farm.

The Company has grown from existing 6 nos. of Technicals to total 10 nos. of Technicals with the launch of products like Acephate, Imidacloprid, Clorpyrifos etc.. Few more products like Acetamiprid, Triazophos, Glyphosate, Thiomethoxam are under launch and facility is being put up to manufacture Pendimethalin. HIL has also sought plan support to set up the zole group of pesticides. In line with the emerging trend to go for environment friendly formulations, HIL has initiated to venture into Suspension Concentrate, Capsulated Suspension and Water Dispersible Granules.

HIL marketing network is spread all over the country with six Regional Sales offices situated in Delhi, Hyderabad, Kolkata Akola, Coimbatore and Ahmedabad. The company has a well equipped Central R&D Complex at UdyogVihar, Gurgaon along with experimental farm.

Performance Highlights

The physical performance of the company during the last three years is given below:

Main Product	Unit	Performance during		
		2015-16	2014-15	2013-14
DDT Formulation	MT	37	53	51

Total revenue of the company registered a decrease of ₹1.04 crore during 2015-16, which went up to ₹323.15 crore in 2015-16 from ₹324.19 crore in 2014-15(Fig.1). However, the profit of the company has gone up by ₹0.23 crore to ₹1.83 crore in 2015-16 from ₹1.60 crore in previous year.

Return on net worth of the company has increased to 1.96% in 2015-16 from 1.73% in 2014-15 (Fig.2). Net profit ratio of the company has also increased to 0.57% in 2015-16 from 0.50% in 2014-15. The current ratio of company is at 1.32:1 during 2015-16 as against 1.38:1 in the previous year. Balance Sheet and Profit & Loss Account of the company and selected financial ratios during the period 2013-14 to 2015-16 can be seen on the adjoining page.




Fig.1




Fig.2

Strategic issue

The company has ventured into new line of activity for which Ministry of Agriculture; Government of India has given recognition as a nodal agency for certified seed production and marketing of field crops and vegetables.

HINDUSTAN INSECTICIDES LTD.

BALANCE SHEET	₹ in Lakhs)		
PARTICULARS	2015-16	2014-15	2013-14
I. EQUITY & LIABILITIES			
AUTHORISED CAPITAL	10000	10000	10000
(1) Shareholders' Funds			
(a) Share Capital			
(i) Central Govt	9133	9133	9133
(ii) Others	0	0	0
(b) Reserves & Surplus	222	123	47
(c) Money received against share warrants	0	0	0
Total Shareholders' Funds (1(a)+1(b)+1(c))	9355	9256	9180
(2) Share application money pending allotment	0	0	0
(3) Non-current Liabilities			
(a) Long Term Borrowings	982	1364	2655
(b) Deferred tax liabilities (Net)	0	0	0
(c) Other Long-term liabilities	728	530	657
(d) Long-term provisions	2863	3002	2849
Total Non-Current Liabilities 3(a) to 3(d)	4573	4896	6161
(4) Current Liabilities			
(a) Short Term Borrowings	8072	5931	6441
(b) Trade Payables	6325	7307	6569
(c) Other current liabilities	7793	7347	4516
(d) Short-term provisions	908	974	704
Total Current Liabilities 4(a) to 4(d)	23098	21559	18230
TOTAL EQUITY & LIABILITIES (1+2+3+4)	37026	35711	33571
II. ASSETS			
(1) Non-Current Assets			
(a) Total Gross Fixed Assets	15311	14688	13310
(ai) Accumulated Depreciation, Depletion & Amortisation	10919	10453	9913
(aii) Accumulated Impairment	0	0	0
(b) Total Net Fixed Assets ((a)-(ai)-(aii))	4392	4235	3397
(c) Capital work in progress	1140	940	1796
(d) Intangible assets under developmet	0	0	0
(e) Non-Current Investments	5	5	5
(f) Deferred Tax Assets (Net)	0	0	0
(g) Long Term Loans and Advances	783	673	710
(h) Other Non-Current Assets	109	122	572
Total Non-Current Assets (b+c+d+e+f+g+h)	6429	5975	6480
(2) Current Assets			
(a) Current Investments	0	0	0
(b) Inventories	7957	10847	6771
(c) Trade Recievables	20024	16258	18881
(d) Cash & Bank Balance	856	752	419
(e) Short-term Loans & Advances	1760	1879	250
(f) Other Current Assets	0	0	770
Total Current Assets (a+b+c+d+e+f)	30597	29736	27091
TOTAL ASSETS (1+2)	37026	35711	33571
Important Indicators			
(i) Investment	10115	10497	11788
(ii) Capital Employed	10337	10620	11835
(iii) Net Worth	9355	9256	9180
(iv) Net Current Assets	7499	8177	8861
(v) Cost of Sales	30821	31191	29729
(vi) Net Value Added (at market price)	13678	14227	12260
(vii) Total Regular Employees (Nos.)	1115	1210	1212
(viii) Avg. Monthly Emoluments per Employee(₹)	77212	76047	62961

PROFIT & LOSS ACCOUNT	₹ in Lakhs)		
PARTICULARS	2015-16	2014-15	2013-14
(I) Revenue from Operations (Gross)	33475	33991	33035
Less : Excise Duty	1444	1948	2957
Revenue from Operations (Net)	32031	32043	30078
(II) Other Income	284	376	748
(III) Total Revenue (I+II)	32315	32419	30826
(IV) Expenditure on:			
(a) Cost of materials consumed	10667	14391	12745
(b) Purchase of stock-in-trade	0	0	0
(c) Changes in inventories of finished goods, work-in-progress and stock in trade	1741	-2764	1112
(d) Stores & Spares	19	51	39
(e) Power & Fuel	1579	2353	2449
(f) Salary, Wages & Benefits/Employees Expense	10331	11042	9157
(g) Other Operating/direct/manufacturing Expenses	2906	3362	1486
(h) Rent, Royalty & Cess	81	76	0
(i) Loss on sale of Assets/Investments	0	0	0
(j) Other Expenses	3001	2178	2350
Total Expenditure (IV (a to j))	30325	30689	29338
(V) PROFIT BEFORE DEPRECIATION, & IMPAIRMENT, FINANCE CHARGES/INTEREST, EXCEPTIONAL & EXTRAORDINARY ITEMS & TAXES (PBDIET)(III-IV)	1990	1730	1488
(VI) Depreciation, Depletion & Amortisation	496	502	391
(VII) Impairment	0	0	0
(VIII) PROFIT BEFORE FINANCE COST/INTEREST, EXCEPTIONAL, EXTRA-ORDINARY ITEMS & TAXES (PBIET)(V-VI-VII)	1494	1228	1097
(IX) Finance Cost			
(a) On Central Government Loans	428	119	216
(b) On Foreign Loans	0	0	0
(c) Others	1064	905	831
(d) Less Finance Cost Capitalised	228	0	140
(e) Charged to P & L Account (a+b+c -d)	1264	1024	907
(X) PROFIT BEFORE EXCEPTIONAL & EXTRA-ORDINARY ITEMS & TAX (PBEET)(VIII-IXe)	230	204	190
(XI) Exceptional Items	47	0	0
(XII) PROFIT BEFORE EXTRA-ORDINARY ITEMS & TAX (PBET)(X-XI)	183	204	190
(XIII) Extra-Ordinary Items	0	0	0
(XIV) PROFIT BEFORE TAX (PBT)(XII-XIII)	183	204	190
(XV) TAX PROVISIONS	0	44	5
(XVI) NET PROFIT / LOSS FOR THE PERIOD FROM CONTINUING OPERATIONS AFTER TAX(XIV-XV)	183	160	185
(XVII) Profit/Loss from discontinuing operations	0	0	0
(XVIII) Tax expenses of discontinuing operations	0	0	0
(XIX) Profit/Loss from discontinuing operations (after Tax)(XVII-XVIII)	0	0	0
(XX) Profit/Loss for the period (XVI+XIX)	183	160	185
Financial Ratios			
(i) Sales : Capital Employed	309.87	301.72	254.14
(ii) Cost of Sales : Sales	96.22	97.34	98.84
(iii) Salary/Wages : Sales	32.25	34.46	30.44
(iv) Net Profit : Net Worth	1.96	1.73	2.02
(v) Debt : Equity	0.11	0.15	0.29
(vi) Current Ratio	1.32	1.38	1.49
(vii) Trade Recievables : Sales	62.51	50.74	62.77
(viii) Total Inventory : Sales	24.84	33.85	22.51

Hindustan Organic Chemicals Ltd.

PO: Rasayani, Maharashtra – 410 207

www.hocl.gov.in

The Company

Hindustan Organic Chemicals Limited (HOC) was set up by the Government of India in 1960 with the objective of attaining self-reliance in basic organic chemical's needs. In fact, this was the first endeavour to indigenize manufacture of basic chemicals and to reduce country's dependence on import of vital organic chemicals. HOC, started as small chemical unit, has today acquired the status of a multi-unit company.

HOCL is a schedule 'B' listed CPSE in Chemicals & Pharmaceuticals sector under the administrative control of M/o Chemicals and Fertilizers, D/o Chemicals and Petrochemicals with 58.78% shareholding by the Government of India. The company employed 957 regular employees (Executives 354 and Non-executives 603) as on 31.3.2016. Its registered office is at Rasayani, Raigad District and corporate office is at Mumbai, Maharashtra.

Vision / Mission

The vision of the company is to produce and market basic chemicals efficiently and economically in an environment friendly manner.

The mission of the company is to maintain optimum level of efficiency and productivity in the use of resources and secure optimum return on investment.

Industrial / Business Operations

HOCL is involved in production of chemicals and intermediaries. The main products of the company are Phenol, Acetone, Formaldehyde, Nitrobenzene, Aniline, and Conc. Nitric Acid. N_2O_4 . It is operating through its two units at Rasayani, Raigad District in Maharashtra and at Ambalamugul, Kochi in Kerala. The company also has one subsidiary i.e. M/s Hindustan Fluorocarbons Limited with a shareholding of 56.43%. The company also has one Joint Venture namely HOC-Chematur Ltd. However, there is no plan to conduct any business in future.

Performance Highlights

The physical performance of the company during the last three years is given below:

Main Segments	Unit	Performance during		
		2015-16	2014-15	2013-14
Total Products	MT	25905	45847	51798

Total revenue of the company registered a decrease of ₹44.42 crore during 2015-16, which went down to ₹114.04 crore in 2015-16 from ₹158.46 crore in 2014-15 due to decrease in production and the turnover (Fig.1). The loss of the company has also gone down by ₹41.58 crore to ₹(-) 173.91 crore in 2015-16, from ₹(-) 215.49 crore in previous year.

The company is having negative net worth. Net profit ratio of the company was (-) 159.33% in 2015-16 as against of (-) 143.54% in 2014-15 (Fig.2). The current ratio of company is at 0.16:1 during 2015-16 as against 0.28:1 in the previous year. Balance Sheet and Profit & Loss Account of the company and selected financial ratios

during the period 2013-14 to 2015-16 can be seen on the adjoining page.




Fig.1




Fig.2

Strategic issue

As per BIFR Summary Record of Proceedings of the Hearing of HOCL Case No. 501/2014 held on 22-07-2015 before the Bench, BIFR declared the Company as sick under Section 3(1)(o) of the Act and appointed State Bank of India as the Operating Agency with directions to prepare a viability study report and revival scheme for the Company, if feasible, keeping in view the provisions of Section 18 of the Act and the guidelines given. BIFR also directed the Company to submit the Draft Rehabilitation Proposal (DRP) with in a period of 8 weeks considering the Cutoff Date (COD) as 31-3-2015. BIFR directions also include among other directions, that OA to submit its report thereof before the next date of the hearing (on 4-11-2015) and to examine the DRP on its receipt from the Company etc. Accordingly, during September, 2015 Company had submitted HOCL Revival Study Report of the consultants, to the Administrative Ministry for consideration and a copy thereof to the OA, SBI as per directions. As at the BIFR Board, consequent to demitting of office by Hon'ble Member, all hearings w.e.f. 28th October, 2015 listed before the Bench of BIFR were postponed till further orders and hence the matter of HOCL was pending in BIFR till a Bench is constituted in BIFR. Later at BIFR, the Bench was constituted and hearing is resumed in April, 2016.

HINDUSTAN ORGANIC CHEMICALS LTD.

BALANCE SHEET	(₹ in Lakhs)		
PARTICULARS	2015-16	2014-15	2013-14
I. EQUITY & LIABILITIES			
AUTHORISED CAPITAL	37000	37000	37000
(1) Shareholders' Funds			
(a) Share Capital			
(i) Central Govt	30948	30948	30948
(ii) Others	2779	2779	2779
(b) Reserves & Surplus	-102877	-85547	-63036
(c) Money received against share warrants	0	0	0
Total Shareholders' Funds (1(a)+1(b)+1(c))	-69150	-51820	-29309
(2) Share application money pending allotment	0	0	0
(3) Non-current Liabilities			
(a) Long Term Borrowings	28327	27618	13752
(b) Deferred tax liabilities (Net)	0	0	0
(c) Other Long-term liabilities	0	136	35
(d) Long-term provisions	7878	8200	7619
Total Non-Current Liabilities 3(a) to 3(d)	36205	35954	21406
(4) Current Liabilities			
(a) Short Term Borrowings	4041	5291	7242
(b) Trade Payables	16140	11433	12938
(c) Other current liabilities	35117	26950	20415
(d) Short-term provisions	1260	1298	1588
Total Current Liabilities 4(a) to 4(d)	56558	44972	42183
TOTAL EQUITY & LIABILITIES (1+2+3+4)	23613	29106	34280
II. ASSETS			
(1) Non-Current Assets			
(a) Total Gross Fixed Assets	64823	63979	66755
(ai) Accumulated Depreciation, Depletion & Amortisation	53156	52052	53207
(aii) Accumulated Impairment	1594	248	234
(b) Total Net Fixed Assets ((a)-(ai)-(aii))	10073	11679	13314
(c) Capital work in progress	433	1067	3698
(d) Intangible assets under developmet	0	0	0
(e) Non-Current Investments	890	890	1111
(f) Deferred Tax Assets (Net)	0	0	0
(g) Long Term Loans and Advances	3141	2861	2937
(h) Other Non-Current Assets	0	0	0
Total Non-Current Assets (b+c+d+e+f+g+h)	14537	16497	21060
(2) Current Assets			
(a) Current Investments	0	0	0
(b) Inventories	3132	5197	5169
(c) Trade Recievables	641	2198	910
(d) Cash & Bank Balance	234	185	2446
(e) Short-term Loans & Advances	4851	4796	4381
(f) Other Current Assets	218	233	314
Total Current Assets (a+b+c+d+e+f)	9076	12609	13220
TOTAL ASSETS (1+2)	23613	29106	34280
Important Indicators			
(i) Investment	62054	61345	47479
(ii) Capital Employed	-40823	-24202	-15557
(iii) Net Worth	-69150	-51820	-29309
(iv) Net Current Assets	-47482	-32363	-28963
(v) Cost of Sales	22184	32178	35172
(vi) Net Value Added (at market price)	-1136	-5470	-2135
(vii) Total Regular Employees (Nos.)	957	1041	1146
(viii) Avg. Monthly Emoluments per Employee(₹)	83708	87296	81479

PROFIT & LOSS ACCOUNT	(₹ in Lakhs)		
PARTICULARS	2015-16	2014-15	2013-14
(I) Revenue from Operations (Gross)	12081	16831	23720
Less : Excise Duty	1166	1818	2604
Revenue from Operations (Net)	10915	15013	21116
(II) Other Income	489	833	932
(III) Total Revenue (I+II)	11404	15846	22048
(IV) Expenditure on:			
(a) Cost of materials consumed	3864	9587	13403
(b) Purchase of stock-in-trade	0	0	8
(c) Changes in inventories of finished goods, work-in-progress and stock in trade	1454	-189	518
(d) Stores & Spares	278	387	703
(e) Power & Fuel	3463	4073	5197
(f) Salary, Wages & Benefits/Employees Expense	9613	10905	11205
(g) Other Operating/direct/manufacturing Expenses	613	505	659
(h) Rent, Royalty & Cess	31	47	83
(i) Loss on sale of Assets/Investments	0	1	185
(j) Other Expenses	418	5969	1554
Total Expenditure (IV (a to j))	19734	31285	33515
(V) PROFIT BEFORE DEPRECIATION, & IMPAIRMENT, FINANCE CHARGES/INTEREST, EXCEPTIONAL & EXTRAORDINARY ITEMS & TAXES (PBDIET)(III-IV)	-8330	-15439	-11467
(VI) Depreciation, Depletion & Amortisation	856	880	1737
(VII) Impairment	1594	14	105
(VIII) PROFIT BEFORE FINANCE COST/INTEREST, EXCEPTIONAL, EXTRA-ORDINARY ITEMS & TAXES (PBIET)(V-VI-VII)	-10780	-16333	-13309
(IX) Finance Cost			
(a) On Central Government Loans	1115	949	1981
(b) On Foreign Loans	0	0	0
(c) Others	5496	4178	2281
(d) Less Finance Cost Capitalised	0	0	0
(e) Charged to P & L Account (a+b+c -d)	6611	5127	4262
(X) PROFIT BEFORE EXCEPTIONAL & EXTRA-ORDINARY ITEMS & TAX (PBEET)(VIII-IXe)	-17391	-21460	-17571
(XI) Exceptional Items	0	89	114
(XII) PROFIT BEFORE EXTRA-ORDINARY ITEMS & TAX (PBET)(X-XI)	-17391	-21549	-17685
(XIII) Extra-Ordinary Items	0	0	0
(XIV) PROFIT BEFORE TAX (PBT)(XII-XIII)	-17391	-21549	-17685
(XV) TAX PROVISIONS	0	0	0
(XVI) NET PROFIT / LOSS FOR THE PERIOD FROM CONTINUING OPERATIONS AFTER TAX(XIV-XV)	-17391	-21549	-17685
(XVII) Profit/Loss from discontinuing operations	0	0	0
(XVIII) Tax expenses of discontinuing operations	0	0	0
(XIX) Profit/Loss from discontinuing operations (after Tax)(XVII-XVIII)	0	0	0
(XX) Profit/Loss for the period (XVI+XIX)	-17391	-21549	-17685
Financial Ratios			
(i) Sales : Capital Employed	-26.74	-62.03	-135.73
(ii) Cost of Sales : Sales	203.24	214.33	166.57
(iii) Salary/Wages : Sales	88.07	72.64	53.06
(iv) Net Profit : Net Worth	-	-	-
(v) Debt : Equity	0.84	0.82	0.41
(vi) Current Ratio	0.16	0.28	0.31
(vii) Trade Recievables : Sales	5.87	14.64	4.31
(viii) Total Inventory : Sales	28.69	34.62	24.48

HLL Biotech Limited

HLL Bhavan, Poojapura P.O., Thiruvananthapuram, Kerala 695012
www.hllbiotech.com

The Company

HLL Biotech Limited (HBL) is a wholly owned subsidiary company of HLL Lifecare Limited was incorporated on 12.03.2012 with an objective to carry on the business of manufacture and sale of all biological preparations including prophylactic and therapeutic vaccines, pharmaceutical products, preparation and services, Anti-Sera, and Plasma and Hormonal products. The Company has commenced the business operations on 30.01.2015.

HBL is an uncategorized CPSE in Chemicals & Pharmaceuticals Sector under administrative control of Ministry of Health & Family Welfare; Government of India. The Company employed 71 regular employees (Executives- 70 & Non-Executives-1) as on 31.3.2016. The company is registered at Kerala and has its corporate office at Chennai (Tamil Nadu).

Mission/Vision

The vision of the company is to be a world class vaccine manufacturer focusing on development, production and supply of vaccines conforming to the best international standards at affordable cost for strengthening the vaccine and health security of the country through continuous innovation.

The mission of the company is to accomplish the corporate vision, which focuses on the following five key areas:

- Be a socially committed corporate by maintaining highest standards of corporate governance & corporate social responsibility with the motto of eliminating the vaccine preventable disease in the country.
- Strengthen and sustain the immunization coverage of India through better access to cost effective vaccines.
- Building excellence by adopting best technologies and practices for manufacturing and supply of safe & effective vaccines in accordance with current GMP norms.
- Maintain the objective of National Health Policy (NHP) 2002 by ensuring an uninterrupted supply of vaccines, at an affordable price.
- Making available cost effective vaccines for Immunization program in other developing countries in addition to India.

Industrial / Business Operations

The Company initiated its business operation on 30th January 2015 with the launch of Vaccine brand 'PENTAHIL' and 'HIVAC-B'.

The achievements of the company are as follows:

- HBCL has received loan license of liquid pentavalent vaccine (with overages) as an additional product under HBL's existing loan license in January 2016 for a period of five years from the Drugs control Authorities.
- Technology for development and manufacturing of has been finalized for Rabies vaccine, Hepatitis B vaccine, BCG vaccine, HIV Vaccine, Pentavalent vaccine, JE Vaccine.
- Selection of technology for development and manufacturing are in progress for vaccine namely Measles vaccine, Pentavalent vaccine formulation.

Performance Highlights

The physical performance during last two year is given below:

Main Products / Services	Unit	Physical Performance	
		2015-16	2014-15
Vaccine	Vials (No.)	NIL	23195
HIVAC	Vials (No.)	NIL	15699
Pentahil	Vials (No.)	NIL	7496

Total revenue of the company registered a reduction of ₹1.13 crore during 2015-16, which went down from ₹1.19 crore in 2014-15 to ₹0.06 crore in 2015-16. The company posted a net loss of ₹(-) 0.63 crore in 2015-16 as compared to the loss of ₹(-) 0.07 crore in the previous year.

Return on net worth of the company has turned from (-) 0.03% in 2014-15 to (-) 0.23% in 2015-16 (Fig.2). The current ratio of company is at 1.05:1 during 2015-16 as against 8.61:1 in the previous year. Balance Sheet and Profit & Loss Account of the company and selected financial ratios during the period 2014-15 to 2015-16 can be seen on the adjoining page.

HLL BIOTECH LTD.

BALANCE SHEET			
	₹ in Lakhs		
PARTICULARS	2015-16	2014-15	2013-14
I. EQUITY & LIABILITIES			
AUTHORISED CAPITAL	28500	28500	18000
(1) Shareholders' Funds			
(a) Share Capital			
(i) Central Govt	0	0	0
(ii) Others	27489	17801	17801
(b) Reserves & Surplus	-81	-18	-11
(c) Money received against share warrants	0	0	0
Total Shareholders' Funds (1(a)+1(b)+1(c))	27408	17783	17790
(2) Share application money pending allotment	0	4000	0
(3) Non-current Liabilities			
(a) Long Term Borrowings	0	0	0
(b) Deferred tax liabilities (Net)	0	0	0
(c) Other Long-term liabilities	0	0	0
(d) Long-term provisions	37	30	7
Total Non-Current Liabilities 3(a) to 3(d)	37	30	7
(4) Current Liabilities			
(a) Short Term Borrowings	0	0	0
(b) Trade Payables	3302	919	24
(c) Other current liabilities	1045	574	35
(d) Short-term provisions	0	0	0
Total Current Liabilities 4(a) to 4(d)	4347	1493	59
TOTAL EQUITY & LIABILITIES (1+2+3+4)	31792	23306	17856
II. ASSETS			
(1) Non-Current Assets			
(a) Total Gross Fixed Assets	409	360	250
(ai) Accumulated Depreciation, Depletion & Amortisation	218	129	36
(aii) Accumulated Impairment	0	0	0
(b) Total Net Fixed Assets ((a)-(ai)-(aii))	191	231	214
(c) Capital work in progress	25443	7242	1935
(d) Intangible assets under developmet	969	709	311
(e) Non-Current Investments	0	0	0
(f) Deferred Tax Assets (Net)	8	4	0
(g) Long Term Loans and Advances	613	2188	2056
(h) Other Non-Current Assets	0	80	1
Total Non-Current Assets (b+c+d+e+f+g+h)	27224	10454	4517
(2) Current Assets			
(a) Current Investments	0	0	0
(b) Inventories	71	81	33
(c) Trade Recievables	0	16	0
(d) Cash & Bank Balance	2382	11234	13023
(e) Short-term Loans & Advances	1545	1481	220
(f) Other Current Assets	570	40	63
Total Current Assets (a+b+c+d+e+f)	4568	12852	13339
TOTAL ASSETS (1+2)	31792	23306	17856
Important Indicators			
(i) Investment	27489	21801	17801
(ii) Capital Employed	27408	21783	17790
(iii) Net Worth	27408	21783	17790
(iv) Net Current Assets	221	11359	13280
(v) Cost of Sales	73	130	0
(vi) Net Value Added (at market price)	-67	127	144
(vii) Total Regular Employees (Nos.)	71	39	39
(viii) Avg. Monthly Emoluments per Employee(₹)	0	11538	0
2015-16 PROVISIONAL			

PROFIT & LOSS ACCOUNT			
	₹ in Lakhs		
PARTICULARS	2015-16	2014-15	2013-14
(I) Revenue from Operations (Gross)	6	115	0
Less : Excise Duty	0	0	0
Revenue from Operations (Net)	6	115	0
(II) Other Income	0	4	0
(III) Total Revenue (I+II)	6	119	0
(IV) Expenditure on:			
(a) Cost of materials consumed	0	38	0
(b) Purchase of stock-in-trade	0	0	0
(c) Changes in inventories of finished goods, work-in-progress and stock in trade	18	-36	0
(d) Stores & Spares	0	0	0
(e) Power & Fuel	0	0	0
(f) Salary, Wages & Benefits/Employees Expense	0	54	0
(g) Other Operating/direct/manufacturing Expenses	16	27	0
(h) Rent, Royalty & Cess	0	0	0
(i) Loss on sale of Assets/Investments	0	0	0
(j) Other Expenses	0	0	0
Total Expenditure (IV (a to j))	34	83	0
(V) PROFIT BEFORE DEPRECIATION, & IMPAIRMENT, FINANCE CHARGES/INTEREST, EXCEPTIONAL & EXTRAORDINARY ITEMS & TAXES (PBDIEET)(III-IV)	-28	36	0
(VI) Depreciation, Depletion & Amortisation	39	47	0
(VII) Impairment	0	0	0
(VIII) PROFIT BEFORE FINANCE COST/INTEREST, EXCEPTIONAL, EXTRA-ORDINARY ITEMS & TAXES (PBIEET)(V-VI-VII)	-67	-11	0
(IX) Finance Cost			
(a) On Central Government Loans	0	0	0
(b) On Foreign Loans	0	0	0
(c) Others	0	0	0
(d) Less Finance Cost Capitalised	0	0	0
(e) Charged to P & L Account (a+b+c -d)	0	0	0
(X) PROFIT BEFORE EXCEPTIONAL & EXTRA-ORDINARY ITEMS & TAX (PBEET)(VIII-IXe)	-67	-11	0
(XI) Exceptional Items	0	0	0
(XII) PROFIT BEFORE EXTRA-ORDINARY ITEMS & TAX (PBET)(X-XI)	-67	-11	0
(XIII) Extra-Ordinary Items	0	0	0
(XIV) PROFIT BEFORE TAX (PBT)(XII-XIII)	-67	-11	0
(XV) TAX PROVISIONS	-4	-4	0
(XVI) NET PROFIT / LOSS FOR THE PERIOD FROM CONTINUING OPERATIONS AFTER TAX(XIV-XV)	-63	-7	0
(XVII) Profit/Loss from discontinuing operations	0	0	0
(XVIII) Tax expenses of discontinuing operations	0	0	0
(XIX) Profit/Loss from discontinuing operations (after Tax)(XVII-XVIII)	0	0	0
(XX) Profit/Loss for the period (XVI+XIX)	-63	-7	0
Financial Ratios			
(i) Sales : Capital Employed	0.02	0.53	0
(ii) Cost of Sales : Sales	1216.67	113.04	0
(iii) Salary/Wages : Sales	0	46.96	0
(iv) Net Profit : Net Worth	-0.23	-0.03	0
(v) Debt : Equity	0	0	0
(vi) Current Ratio	1.05	8.61	226.08
(vii) Trade Recievables : Sales	0	13.91	0
(viii) Total Inventory : Sales	1183.33	70.43	0

IDPL (Tamilnadu) Ltd.

IDPL (Tamil Nadu) Ltd., Nandambakkam, Guindy Chennai, Tamil Nadu -600089
www.idpl.gov.in

The Company

IDPL (Tamilnadu) Ltd. (IDPL-TN) was incorporated in 1994 with the objective of manufacturing surgical instruments, drugs, hospital equipments and aids and appliances for handicapped persons. It was established as a wholly owned subsidiary of the Indian Drugs & Pharmaceuticals Ltd. (IDPL).

IDPL (Tamilnadu) Ltd. is an uncategorised CPSE in Chemicals & Pharmaceuticals sector under the administrative control of M/o Chemicals and Fertilizers, Department of Pharmaceuticals. The company employed 124 regular employees (Executives-13 and Non-executives 111) as on 31.3.2016. Its registered and corporate offices are at Chennai, Tamilnadu.

Vision / Mission

The vision/mission of the company are to produce Medicines for Millions – at affordable prices.

Industrial / Business Operations

The company is involved in production of tablets and capsules. Originally it was an engineering unit for producing surgical instruments. Later on it diversified into other activities like manufacturing of hospital equipment tricycles, wheel chair and aids & appliances for the differently abled persons. However due to various reasons the surgical instruments division was shut down in 2001. Now formulations are produced.

Performance Highlights

Total revenue of the company registered an increase of ₹0.92 crore during 2015-16, which went up to ₹9.04 crore in 2015-16 from ₹8.12 crore in 2014-15 (Fig.1). The profit of the company has decreased to ₹(-)0.73 crore in 2015-16 from a profit of ₹1.12 crore in 2014-15.

The net worth of the company is negative in 2015-16. Net profit ratio of the company is at (-) 8.08% in 2015-16 as against of 13.79% in 2014-15. The current ratio of company is at 0.08:1 during 2015-16 as against 0.14:1 in the previous year. Balance Sheet and Profit & Loss Account of the company and selected financial ratios during the period 2013-14 to 2015-16 can be seen on the adjoining page.




Fig (1)




Fig (2)

IDPL (TAMILNADU) LTD.

BALANCE SHEET	(₹ in Lakhs)		
PARTICULARS	2015-16	2014-15	2013-14
I. EQUITY & LIABILITIES			
AUTHORISED CAPITAL	400	400	400
(1) Shareholders' Funds			
(a) Share Capital			
(i) Central Govt	0	0	0
(ii) Others	400	400	400
(b) Reserves & Surplus	-4450	-3577	-4264
(c) Money received against share warrants	0	0	0
Total Shareholders' Funds (1(a)+1(b)+1(c))	-4050	-3177	-3864
(2) Share application money pending allotment	0	1727	1727
(3) Non-current Liabilities			
(a) Long Term Borrowings	4465	4196	4466
(b) Deferred tax liabilities (Net)	0	0	0
(c) Other Long-term liabilities	0	150	150
(d) Long-term provisions	0	0	0
Total Non-Current Liabilities 3(a) to 3(d)	4465	4346	4616
(4) Current Liabilities			
(a) Short Term Borrowings	328	2915	2915
(b) Trade Payables	6024	610	610
(c) Other current liabilities	0	73	73
(d) Short-term provisions	0	98	98
Total Current Liabilities 4(a) to 4(d)	6352	3696	3696
TOTAL EQUITY & LIABILITIES (1+2+3+4)	6767	6592	6175
II. ASSETS			
(1) Non-Current Assets			
(a) Total Gross Fixed Assets	5994	6020	6173
(ai) Accumulated Depreciation, Depletion & Amortisation	23	27	509
(aii) Accumulated Impairment	0	0	0
(b) Total Net Fixed Assets ((a)-(ai)-(aii))	5971	5993	5664
(c) Capital work in progress	0	0	0
(d) Intangible assets under developmet	0	0	0
(e) Non-Current Investments	0	0	0
(f) Deferred Tax Assets (Net)	0	0	0
(g) Long Term Loans and Advances	299	0	0
(h) Other Non-Current Assets	0	98	98
Total Non-Current Assets (b+c+d+e+f+g+h)	6270	6091	5762
(2) Current Assets			
(a) Current Investments	0	0	0
(b) Inventories	174	148	151
(c) Trade Recievables	309	220	220
(d) Cash & Bank Balance	14	55	33
(e) Short-term Loans & Advances	0	9	9
(f) Other Current Assets	0	69	0
Total Current Assets (a+b+c+d+e+f)	497	501	413
TOTAL ASSETS (1+2)	6767	6592	6175
Important Indicators			
(i) Investment	4865	6323	6593
(ii) Capital Employed	415	2746	2329
(iii) Net Worth	-4050	-1450	-2137
(iv) Net Current Assets	-5855	-3195	-3283
(v) Cost of Sales	977	700	1278
(vi) Net Value Added (at market price)	82	262	-70
(vii) Total Regular Employees (Nos.)	124	124	112
(viii) Avg. Monthly Emoluments per Employee(₹)	10417	10081	12202
2015-16 PROVISIONAL			

PROFIT & LOSS ACCOUNT	(₹ in Lakhs)		
PARTICULARS	2015-16	2014-15	2013-14
(I) Revenue from Operations (Gross)	904	812	1044
Less : Excise Duty	0	0	0
Revenue from Operations (Net)	904	812	1044
(II) Other Income	0	0	0
(III) Total Revenue (I+II)	904	812	1044
(IV) Expenditure on:			
(a) Cost of materials consumed	572	271	708
(b) Purchase of stock-in-trade	0	0	0
(c) Changes in inventories of finished goods, work-in-progress and stock in trade	-24	3	27
(d) Stores & Spares	0	0	0
(e) Power & Fuel	0	0	0
(f) Salary, Wages & Benefits/Employees Expense	155	150	164
(g) Other Operating/direct/manufacturing Expenses	240	250	263
(h) Rent, Royalty & Cess	0	0	0
(i) Loss on sale of Assets/Investments	0	0	0
(j) Other Expenses	11	0	87
Total Expenditure (IV (a to j))	954	674	1249
(V) PROFIT BEFORE DEPRECIATION, & IMPAIRMENT, FINANCE CHARGES/INTEREST, EXCEPTIONAL & EXTRAORDINARY ITEMS & TAXES (PBDIET)(III-IV)	-50	138	-205
(VI) Depreciation, Depletion & Amortisation	23	26	29
(VII) Impairment	0	0	0
(VIII) PROFIT BEFORE FINANCE COST/INTEREST, EXCEPTIONAL, EXTRA-ORDINARY ITEMS & TAXES (PBIEET)(V-VI-VII)	-73	112	-234
(IX) Finance Cost			
(a) On Central Government Loans	0	0	0
(b) On Foreign Loans	0	0	0
(c) Others	0	0	0
(d) Less Finance Cost Capitalised	0	0	0
(e) Charged to P & L Account (a+b+c -d)	0	0	0
(X) PROFIT BEFORE EXCEPTIONAL & EXTRA-ORDINARY ITEMS & TAX (PBEET)(VIII-IXe)	-73	112	-234
(XI) Exceptional Items	0	0	0
(XII) PROFIT BEFORE EXTRA-ORDINARY ITEMS & TAX (PBET)(X-XI)	-73	112	-234
(XIII) Extra-Ordinary Items	0	0	0
(XIV) PROFIT BEFORE TAX (PBT)(XII-XIII)	-73	112	-234
(XV) TAX PROVISIONS	0	0	0
(XVI) NET PROFIT / LOSS FOR THE PERIOD FROM CONTINUING OPERATIONS AFTER TAX(XIV-XV)	-73	112	-234
(XVII) Profit/Loss from discontinuing operations	0	0	0
(XVIII) Tax expenses of discontinuing operations	0	0	0
(XIX) Profit/Loss from discontinuing operations (after Tax)(XVII-XVIII)	0	0	0
(XX) Profit/Loss for the period (XVI+XIX)	-73	112	-234
Financial Ratios			
(i) Sales : Capital Employed	217.83	29.57	44.83
(ii) Cost of Sales : Sales	108.08	86.21	122.41
(iii) Salary/Wages : Sales	17.15	18.47	15.71
(iv) Net Profit : Net Worth	-	-	-
(v) Debt : Equity	11.16	1.97	2.1
(vi) Current Ratio	0.08	0.14	0.11
(vii) Trade Recievables : Sales	34.18	27.09	21.07
(viii) Total Inventory : Sales	19.25	18.23	14.46

Indian Drugs and Pharmaceuticals Ltd.

IDPL Complex, Delhi-Gurgaon Road, Dundahera, Gurgaon, Haryana - 122 016
www.idpl.gov.in

The Company

Indian Drugs and Pharmaceuticals Ltd. (IDPL) was incorporated on 05.04.1961 with the objective to create self-sufficiency in respect of essential lifesaving medicines in order to free the country from dependence on imports and to provide medicines at affordable prices.

IDPL is a schedule 'B' / BIFR referred CPSE in Chemicals & Pharmaceuticals sector under the administrative control of Ministry of Chemicals and Fertilizers, Department of Pharmaceuticals with 100% shareholding by the Government of India. The company employed 66 regular employees (Executives 32 & Non-Executives 34) as on 31.3.2016. Its registered office is in Gurgaon, Haryana and corporate office is in Delhi.

Mission/Vision

The mission / vision of the company is to manufacture quality drugs for common masses.

Industrial/Business Operations

IDPL is involved in the production and marketing of drugs/formulations. It has three main plants at Rishikesh Uttarakhand, Hyderabad in Telangana and Gurgaon in Haryana and two wholly owned subsidiaries, namely, IDPL (Tamil Nadu) Ltd., at Chennai (Tamil Nadu) and Bihar Drugs & Organic Chemicals Ltd (BDOCL) at Muzaffarpur (Bihar). In addition, IDPL has one Joint Venture Undertaking, promoted in collaboration with the Odisha State Government, namely, Orrisa Drugs & Chemical Ltd. (ODCL), Bhubaneswar.

Performance Highlights

The physical performances of the company for last three years is given below:

Main Products / Services	Unit	Performance during		
		2015-16	2014-15	2013-14
Tablet	Lakh No.	11259	10104	7813
Capsules	Lakh No.	1285	985	1534

Total revenue of the company registered an increase of ₹25.04 crore during 2015-16, which went up to ₹106.10crore in 2015-16 from ₹81.06 crore in 2014-15(Fig.1). The loss of the company has gone down by ₹1.13 crore to ₹(-) 166.08 crore in 2015-16, from ₹(-) 167.21 crore in previous year due increase in revenue from operation and reduction in staff cost.

Net worth of the company is negative. The current ratio of company is at 0.05:1 during 2015-16 and 0.04:1 in the previous year. Balance Sheet and Profit & Loss Account of the

company and selected financial ratios during the period 2013-14 to 2015-16 can be seen on the adjoining page.




Fig 1

Strategic issue

The company is referred to BIFR and BRPSE. The first revival package had failed and the 2nd revival package is yet to be approved. BRPSE recommended for revival as a CPSE on 9.3.2007, inter alia, with revival package of ₹3222.76 Crore (cash assistance of ₹361 Crore and non-cash assistance of ₹2861.76 Crore) from Government of India and also merger of its subsidiaries viz. IDPL (Tamil Nadu) Ltd., Chennai & Bihar Drugs & Organic Chemicals Ltd., Muzaffarpur, Bihar into IDPL. Based on recommendations of BRPSE, revival proposal was submitted to Cabinet. It was decided to refer the proposal to GoM. Based on the suggestion of GoM, a Consultant was appointed for preparation of revival plan. Based on the report of the Consultant, a revival plan sent by the Company is under consideration of the Ministry.

A revised DRA again prepared by IDPL in consultation with IDBI (OA) taking cut-off date as 31st March, 2011. BIFR observation that cut-off date needed the approval of BIFR bench. Thereafter in the BIFR meeting held on 20.08.2014 cut-off date was approved as 31.03.2014. Accordingly, the revised updated DRS has been prepared taking cut-off date 31.03.2014 and submitted to the DoP / Ministry in January 2015 for consideration and approval.

INDIAN DRUGS & PHARMACEUTICALS LTD.

BALANCE SHEET	(₹ in Lakhs)		
PARTICULARS	2015-16	2014-15	2013-14
I. EQUITY & LIABILITIES			
AUTHORISED CAPITAL	12000	12000	12000
(1) Shareholders' Funds			
(a) Share Capital			
(i) Central Govt	11688	11688	11688
(ii) Others	0	0	0
(b) Reserves & Surplus	-726415	-710067	-693241
(c) Money received against share warrants	0	0	0
Total Shareholders' Funds (1(a)+1(b)+1(c))	-714727	-698379	-681553
(2) Share application money pending allotment	0	0	0
(3) Non-current Liabilities			
(a) Long Term Borrowings	526566	509587	492138
(b) Deferred tax liabilities (Net)	0	0	0
(c) Other Long-term liabilities	10852	9803	9447
(d) Long-term provisions	1022	1197	1399
Total Non-Current Liabilities 3(a) to 3(d)	538440	520587	502984
(4) Current Liabilities			
(a) Short Term Borrowings	172391	172372	171710
(b) Trade Payables	28907	28758	28665
(c) Other current liabilities	5940	4816	4256
(d) Short-term provisions	66	189	172
Total Current Liabilities 4(a) to 4(d)	207304	206135	204803
TOTAL EQUITY & LIABILITIES (1+2+3+4)	31017	28343	26234
II. ASSETS			
(1) Non-Current Assets			
(a) Total Gross Fixed Assets	14176	14061	14037
(ai) Accumulated Depreciation, Depletion & Amortisation	12923	12305	12065
(aii) Accumulated Impairment	0	0	0
(b) Total Net Fixed Assets ((a)-(ai)-(aii))	1253	1756	1972
(c) Capital work in progress	1856	1183	688
(d) Intangible assets under developmet	0	0	0
(e) Non-Current Investments	3072	3072	3072
(f) Deferred Tax Assets (Net)	0	0	0
(g) Long Term Loans and Advances	13739	12860	12194
(h) Other Non-Current Assets	45	649	325
Total Non-Current Assets (b+c+d+e+f+g+h)	19965	19520	18251
(2) Current Assets			
(a) Current Investments	0	0	0
(b) Inventories	1398	1457	980
(c) Trade Recievables	3396	2906	2363
(d) Cash & Bank Balance	4669	3029	3456
(e) Short-term Loans & Advances	1520	1338	1102
(f) Other Current Assets	69	93	82
Total Current Assets (a+b+c+d+e+f)	11052	8823	7983
TOTAL ASSETS (1+2)	31017	28343	26234
Important Indicators			
(i) Investment	538254	521275	503826
(ii) Capital Employed	-188161	-188792	-189415
(iii) Net Worth	-721003	-698379	-681553
(iv) Net Current Assets	-196252	-197312	-196820
(v) Cost of Sales	9589	7822	8280
(vi) Net Value Added (at market price)	1293	1152	431
(vii) Total Regular Employees (Nos.)	66	95	114
(viii) Avg. Monthly Emoluments per Employee(₹)	104798	74386	77924
2015-16 PROVISIONAL			

PROFIT & LOSS ACCOUNT	(₹ in Lakhs)		
PARTICULARS	2015-16	2014-15	2013-14
(I) Revenue from Operations (Gross)	8714	6355	5875
Less : Excise Duty	292	199	177
Revenue from Operations (Net)	8422	6156	5698
(II) Other Income	2188	1950	1948
(III) Total Revenue (I+II)	10610	8106	7646
(IV) Expenditure on:			
(a) Cost of materials consumed	2988	2195	2302
(b) Purchase of stock-in-trade	2431	2148	1990
(c) Changes in inventories of finished goods, work-in-progress and stock in trade	177	-239	2
(d) Stores & Spares	0	0	0
(e) Power & Fuel	421	393	397
(f) Salary, Wages & Benefits/Employees Expense	830	848	1066
(g) Other Operating/direct/manufacturing Expenses	0	322	370
(h) Rent, Royalty & Cess	26	20	0
(i) Loss on sale of Assets/Investments	0	0	0
(j) Other Expenses	2603	2000	2027
Total Expenditure (IV (a to j))	9476	7687	8154
(V) PROFIT BEFORE DEPRECIATION, & IMPAIRMENT, FINANCE CHARGES/INTEREST, EXCEPTIONAL & EXTRAORDINARY ITEMS & TAXES (PBDIET)(III-IV)	1134	419	-508
(VI) Depreciation, Depletion & Amortisation	113	135	126
(VII) Impairment	0	0	0
(VIII) PROFIT BEFORE FINANCE COST/INTEREST, EXCEPTIONAL, EXTRA-ORDINARY ITEMS & TAXES (PBIET)(V-VI-VII)	1021	284	-634
(IX) Finance Cost			
(a) On Central Government Loans	16979	16949	16809
(b) On Foreign Loans	0	0	0
(c) Others	66	56	19
(d) Less Finance Cost Capitalised	0	0	0
(e) Charged to P & L Account (a+b+c -d)	17045	17005	16828
(X) PROFIT BEFORE EXCEPTIONAL & EXTRA-ORDINARY ITEMS & TAX (PBEET)(VIII-IXe)	-16024	-16721	-17462
(XI) Exceptional Items	0	0	1
(XII) PROFIT BEFORE EXTRA-ORDINARY ITEMS & TAX (PBET)(X-XI)	-16024	-16721	-17463
(XIII) Extra-Ordinary Items	584	0	0
(XIV) PROFIT BEFORE TAX (PBT)(XII-XIII)	-16608	-16721	-17463
(XV) TAX PROVISIONS	0	0	0
(XVI) NET PROFIT / LOSS FOR THE PERIOD FROM CONTINUING OPERATIONS AFTER TAX(XIV-XV)	-16608	-16721	-17463
(XVII) Profit/Loss from discontinuing operations	0	0	0
(XVIII) Tax expenses of discontinuing operations	0	0	0
(XIX) Profit/Loss from discontinuing operations (after Tax)(XVII-XVIII)	0	0	0
(XX) Profit/Loss for the period (XVI+XIX)	-16608	-16721	-17463
Financial Ratios			
(i) Sales : Capital Employed	-4.48	-3.26	-3.01
(ii) Cost of Sales : Sales	113.86	127.06	145.31
(iii) Salary/Wages : Sales	9.86	13.78	18.71
(iv) Net Profit : Net Worth	-	-	-
(v) Debt : Equity	45.05	43.6	42.11
(vi) Current Ratio	0.05	0.04	0.04
(vii) Trade Recievables : Sales	40.32	47.21	41.47
(viii) Total Inventory : Sales	16.6	23.67	17.2

Indian Medicines & Pharmaceutical Corporation Ltd.

Mohan, (Via Ramnagar, Distt. Almora, Uttarakhand - 244 715
www.impclmohan.nic.in

The Company

Indian Medicines & Pharmaceutical Corp. Ltd. (IMPCL) was incorporated on 12.7.1978 with the objective to manufacture Ayurvedic, Unani and Siddha medicines on the basis of classical principles and approved formulae both in domestic and international Market.

IMPCL is a schedule 'D' Miniratna CPSE in Chemicals & Pharmaceuticals sector under the administrative control of the M/o Health and Family Welfare, D/o Ayush with 98.02% shareholding by the Government of India. The remaining equity holding is with state Government of Uttarakhand. The company employed 131 regular employees (Executives-9 & Non-Executives-122) as on 31.3.2016. Its registered and corporate offices are at District Almora in Uttarakhand.

Vision / Mission

The vision of the company is to become the best ayurvedic and unani medicines manufacturing company in India and contribute to health care through excellence in performance, total customer satisfaction and improved technologies.

The mission of the company is to make available authentic, classical ayurvedic and unani medicines and enhance capacity portfolio covering nutraceuticals, health supplements and cosmetics based on herbals.

Industrial / Business Operations

IMPCL is involved in production of Ayurvedic and Unani Medicines through its single operating unit at Mohan (Almora), Uttarakhand. The installed capacity of the plant are 179 nos. of Ayurvedic and 79nos of Unani Medicines. Total products of Ayurvedic and Unani medicines are around 296.

The company has one sale counter at Janakpuri, New Delhi.

Performance Highlights

The physical performance of the company for last three years is given below:

Main Products	Unit	Performance during		
		2015-16	2014-15	2013-14
Ayurvedic & Unani Medicines	Kg./Ltr.	721992	622897	741639

Total revenue of the company registered an increase of ₹3.15 crore during 2015-16, which went up to ₹36.71 crore

in 2015-16 from ₹33.56crore in 2014-15 (Fig.1). The loss of the company has also gone up by ₹3.20 crore to ₹(-) 3.32 crore in 2014-15, from ₹(-) 0.14 crore in previous year.

Return on net worth of the company has decreased to (-) 6.32% in 2015-16 from (-) 0.27% in 2014-15 (Fig.2). Net profit ratio of the company decreased to (-) 9.15% in 2015-16 from (-) 0.37 % in 2014-15. The current ratio of company is at 1.33:1 during 2015-16 as against 1.75:1 in the previous year. Balance Sheet and Profit & Loss Account of the company and selected financial ratios during the period 2013-14 to 2015-16 can be seen on the adjoining page.




Fig. 1




Fig.2

INDIAN MEDICINES & PHARMACEUTICAL CORPN. LTD.

BALANCE SHEET	₹ in Lakhs		
PARTICULARS	2015-16	2014-15	2013-14
I. EQUITY & LIABILITIES			
AUTHORISED CAPITAL	7500	7500	7500
(1) Shareholders' Funds			
(a) Share Capital			
(i) Central Govt	4830	4002	4002
(ii) Others	98	98	98
(b) Reserves & Surplus	322	1171	1181
(c) Money received against share warrants	0	0	0
Total Shareholders' Funds (1(a)+1(b)+1(c))	5250	5271	5281
(2) Share application money pending allotment	0	0	0
(3) Non-current Liabilities			
(a) Long Term Borrowings	0	0	0
(b) Deferred tax liabilities (Net)	0	0	0
(c) Other Long-term liabilities	0	0	0
(d) Long-term provisions	469	334	305
Total Non-Current Liabilities 3(a) to 3(d)	469	334	305
(4) Current Liabilities			
(a) Short Term Borrowings	-315	296	305
(b) Trade Payables	2131	1848	1871
(c) Other current liabilities	1972	554	260
(d) Short-term provisions	59	51	212
Total Current Liabilities 4(a) to 4(d)	3847	2749	2648
TOTAL EQUITY & LIABILITIES (1+2+3+4)	9566	8354	8234
II. ASSETS			
(1) Non-Current Assets			
(a) Total Gross Fixed Assets	456	443	1257
(ai) Accumulated Depreciation, Depletion & Amortisation	55	71	752
(aii) Accumulated Impairment	0	0	0
(b) Total Net Fixed Assets ((a)-(ai)-(aii))	401	372	505
(c) Capital work in progress	3839	2996	1314
(d) Intangible assets under developmet	0	0	0
(e) Non-Current Investments	0	0	0
(f) Deferred Tax Assets (Net)	111	111	99
(g) Long Term Loans and Advances	98	52	127
(h) Other Non-Current Assets	0	0	0
Total Non-Current Assets (b+c+d+e+f+g+h)	4449	3531	2045
(2) Current Assets			
(a) Current Investments	0	0	0
(b) Inventories	1563	1367	1290
(c) Trade Recievables	2535	2340	2517
(d) Cash & Bank Balance	752	823	2107
(e) Short-term Loans & Advances	143	168	11
(f) Other Current Assets	124	125	264
Total Current Assets (a+b+c+d+e+f)	5117	4823	6189
TOTAL ASSETS (1+2)	9566	8354	8234
Important Indicators			
(i) Investment	4928	4100	4100
(ii) Capital Employed	5250	5271	5281
(iii) Net Worth	5250	5271	5281
(iv) Net Current Assets	1270	2074	3541
(v) Cost of Sales	4003	3352	3475
(vi) Net Value Added (at market price)	990	1125	1491
(vii) Total Regular Employees (Nos.)	131	131	406
(viii) Avg. Monthly Emoluments per Employee(₹)	69466	55407	17919

2015-16 PROVISIONAL

PROFIT & LOSS ACCOUNT	₹ in Lakhs		
PARTICULARS	2015-16	2014-15	2013-14
(I) Revenue from Operations (Gross)	3630	3203	3651
Less : Excise Duty	0	0	0
Revenue from Operations (Net)	3630	3203	3651
(II) Other Income	41	153	224
(III) Total Revenue (I+II)	3671	3356	3875
(IV) Expenditure on:			
(a) Cost of materials consumed	1985	1769	1942
(b) Purchase of stock-in-trade	0	0	-103
(c) Changes in inventories of finished goods, work-in-progress and stock in trade	-62	-33	0
(d) Stores & Spares	1	0	0
(e) Power & Fuel	152	14	154
(f) Salary, Wages & Benefits/Employees Expense	1092	871	873
(g) Other Operating/direct/manufacturing Expenses	571	634	529
(h) Rent, Royalty & Cess	0	0	7
(i) Loss on sale of Assets/Investments	0	0	0
(j) Other Expenses	209	26	0
Total Expenditure (IV (a to j))	3948	3281	3402
(V) PROFIT BEFORE DEPRECIATION, & IMPAIRMENT, FINANCE CHARGES/INTEREST, EXCEPTIONAL & EXTRAORDINARY ITEMS & TAXES (PBDIET)(III-IV)	-277	75	473
(VI) Depreciation, Depletion & Amortisation	55	71	73
(VII) Impairment	0	0	0
(VIII) PROFIT BEFORE FINANCE COST/INTEREST, EXCEPTIONAL, EXTRA-ORDINARY ITEMS & TAXES (PBIET)(V-VI-VII)	-332	4	400
(IX) Finance Cost			
(a) On Central Government Loans	0	0	0
(b) On Foreign Loans	0	0	0
(c) Others	0	24	25
(d) Less Finance Cost Capitalised	0	0	0
(e) Charged to P & L Account (a+b+c -d)	0	24	25
(X) PROFIT BEFORE EXCEPTIONAL & EXTRA-ORDINARY ITEMS & TAX (PBEET)(VIII-IXe)	-332	-20	375
(XI) Exceptional Items	0	0	0
(XII) PROFIT BEFORE EXTRA-ORDINARY ITEMS & TAX (PBET)(X-XI)	-332	-20	375
(XIII) Extra-Ordinary Items	0	0	0
(XIV) PROFIT BEFORE TAX (PBT)(XII-XIII)	-332	-20	375
(XV) TAX PROVISIONS	0	-6	134
(XVI) NET PROFIT / LOSS FOR THE PERIOD FROM CONTINUING OPERATIONS AFTER TAX(XIV-XV)	-332	-14	241
(XVII) Profit/Loss from discontinuing operations	0	0	0
(XVIII) Tax expenses of discontinuing operations	0	0	0
(XIX) Profit/Loss from discontinuing operations (after Tax)(XVII-XVIII)	0	0	0
(XX) Profit/Loss for the period (XVI+XIX)	-332	-14	241
Financial Ratios			
(i) Sales : Capital Employed	69.14	60.77	69.13
(ii) Cost of Sales : Sales	110.28	104.65	95.18
(iii) Salary/Wages : Sales	30.08	27.19	23.91
(iv) Net Profit : Net Worth	-6.32	-0.27	4.56
(v) Debt : Equity	0	0	0
(vi) Current Ratio	1.33	1.75	2.34
(vii) Trade Recievables : Sales	69.83	73.06	68.94
(viii) Total Inventory : Sales	43.06	42.68	35.33

Karnataka Antibiotics and Pharmaceuticals Ltd.

Nirman Bhavan, Dr. Rajkumar Road, 1st Block, Rajaji Nagar Bangalore, Karnataka - 560 010

www.kaplindia.com

The Company

Karnataka Antibiotics and Pharmaceuticals Ltd.,(KAPL) was incorporated on 13.3.1981 as a joint venture company between Hindustan Antibiotics Ltd., and the Government of Karnataka through Karnataka State Industrial Investment and Development Corporation Ltd. (KSIIDC), under the Companies Act, 1956 with an objective to achieve corporate excellence in the field of quality drugs and health care at globally competitive prices. Presently, 59.16% shares of KAPL are held by Government of India and 40.84% by Government of Karnataka.

KAPL is a schedule 'C' CPSE in Chemical & Pharmaceuticals sector under the administrative control of M/o Chemicals and Fertilizers D/o Pharmaceuticals having its registered and corporate office is at Bangalore, Karnataka. The Company employed 712 regular employees (Executives- 239 and Non Executives - 473) as on 31.03.2016.

Vision / Mission

The vision of the company is to achieve excellence in the field of manufacture and marketing of quality drugs and health care products at affordable prices for all.

The mission of the company is to have manufacturing facilities complying with international standards, to strengthen the marketing efforts to achieve 10% growth in exports and private trade market every year, to continuously improve the quality of products and services to enhance Customer Satisfaction, to develop highly motivated multi skilled human resources to increase productivity.

Industrial / Business Operations

KAPL is engaged in manufacturing and marketing of Allopathic Formulations through its operating unit at Bangalore, Karnataka. The company manufactures products like injections, capsules, tablets, syrups and suspensions. The product range of the company comprises of 93 products.

Performance Highlights

The physical performance of the company during the last three years is given below:

Main Product	Unit	Performance during		
		2015-16	2014-15	2013-14
Tablets	No.in Lacs	10998	7191	7587
Capsules	No.in Lacs	2230	1290	1335
Dry Powder Vials	No.in Lacs	548	572	505
Liquid Parenterals	No.in Lacs	639	503	555

Total revenue of the company registered an increase of ₹71.78 crore during 2015-16, which went up to ₹313.62 crore in 2015-16 from ₹241.84 crore in 2014-15 (Fig.1). The profit of the company has gone up by ₹8.45 crore to ₹19.51 crore in 2015-16 from ₹11.06 crore in

previous year due to increase in turnover and reduction in material and overhead cost.

Return on net worth of the company has increased to 15.26% in 2015-16 from 9.99% in 2014-15. Net profit ratio of the company has also increased to 6.25% in 2015-16 from 4.67% in 2014-15 (Fig.2). The current ratio of company is at 1.85:1 during 2015-16 as against 1.81:1 in the previous year. Balance Sheet and Profit & Loss Account of the company and selected financial ratios during the period 2013-14 to 2015-16 can be seen on the adjoining page.




Fig.1




Fig.2

Strategic Issues

The company was basically set up to cater to institutional requirements. However, it is also expanding its presence in retail trade segment and exports in order to ensure sustained growth. As such the company aims to modernize and upgrade the manufacturing facilities, to comply with the international standards, to strengthen its marketing efforts to achieve high growth in Exports and Private Trade Market and to continuously improve the quality of products and services to enhance customer satisfaction.

KARNATAKA ANTIBIOTICS & PHARMACEUTICALS LTD.

BALANCE SHEET	(₹ in Lakhs)		
PARTICULARS	2015-16	2014-15	2013-14
I. EQUITY & LIABILITIES			
AUTHORISED CAPITAL	1500	1500	1500
(1) Shareholders' Funds			
(a) Share Capital			
(i) Central Govt	798	798	798
(ii) Others	551	551	551
(b) Reserves & Surplus	11432	9724	8913
(c) Money received against share warrants	0	0	0
Total Shareholders' Funds (1(a)+1(b)+1(c))	12781	11073	10262
(2) Share application money pending allotment	0	0	0
(3) Non-current Liabilities			
(a) Long Term Borrowings	310	477	412
(b) Deferred tax liabilities (Net)	0	0	0
(c) Other Long-term liabilities	0	0	0
(d) Long-term provisions	1545	1409	1514
Total Non-Current Liabilities 3(a) to 3(d)	1855	1886	1926
(4) Current Liabilities			
(a) Short Term Borrowings	429	452	497
(b) Trade Payables	5866	5530	7457
(c) Other current liabilities	2615	2134	1794
(d) Short-term provisions	670	571	384
Total Current Liabilities 4(a) to 4(d)	9580	8687	10132
TOTAL EQUITY & LIABILITIES (1+2+3+4)	24216	21646	22320
II. ASSETS			
(1) Non-Current Assets			
(a) Total Gross Fixed Assets	4204	3945	3852
(ai) Accumulated Depreciation, Depletion & Amortisation	2640	2307	1883
(aii) Accumulated Impairment	0	0	0
(b) Total Net Fixed Assets ((a)-(ai)-(aii))	1564	1638	1969
(c) Capital work in progress	2623	2325	1961
(d) Intangible assets under developmet	0	0	0
(e) Non-Current Investments	0	0	0
(f) Deferred Tax Assets (Net)	172	120	100
(g) Long Term Loans and Advances	1123	1077	803
(h) Other Non-Current Assets	1043	724	595
Total Non-Current Assets (b+c+d+e+f+g+h)	6525	5884	5428
(2) Current Assets			
(a) Current Investments	0	0	0
(b) Inventories	4576	5051	3759
(c) Trade Recievables	8131	6424	6994
(d) Cash & Bank Balance	4383	3684	5333
(e) Short-term Loans & Advances	596	584	714
(f) Other Current Assets	5	19	92
Total Current Assets (a+b+c+d+e+f)	17691	15762	16892
TOTAL ASSETS (1+2)	24216	21646	22320
Important Indicators			
(i) Investment	1659	1826	1761
(ii) Capital Employed	13091	11550	10674
(iii) Net Worth	12781	11073	10262
(iv) Net Current Assets	8111	7075	6760
(v) Cost of Sales	28298	22436	22592
(vi) Net Value Added (at market price)	12320	9580	8779
(vii) Total Regular Employees (Nos.)	712	728	738
(viii) Avg. Monthly Emoluments per Employee(₹)	70190	60920	58435

PROFIT & LOSS ACCOUNT	(₹ in Lakhs)		
PARTICULARS	2015-16	2014-15	2013-14
(I) Revenue from Operations (Gross)	32954	24917	24565
Less : Excise Duty	1752	1221	1146
Revenue from Operations (Net)	31202	23696	23419
(II) Other Income	160	488	409
(III) Total Revenue (I+II)	31362	24184	23828
(IV) Expenditure on:			
(a) Cost of materials consumed	12946	10225	9219
(b) Purchase of stock-in-trade	2264	2453	3699
(c) Changes in inventories of finished goods, work-in-progress and stock in trade	188	-697	-311
(d) Stores & Spares	58	51	53
(e) Power & Fuel	385	351	329
(f) Salary, Wages & Benefits/Employees Expense	5997	5322	5175
(g) Other Operating/direct/manufacturing Expenses	3815	2732	2634
(h) Rent, Royalty & Cess	122	116	104
(i) Loss on sale of Assets/Investments	0	0	0
(j) Other Expenses	2184	1545	1498
Total Expenditure (IV (a to j))	27959	22098	22400
(V) PROFIT BEFORE DEPRECIATION, & IMPAIRMENT, FINANCE CHARGES/INTEREST, EXCEPTIONAL & EXTRAORDINARY ITEMS & TAXES (PBDIET)(III-IV)	3403	2086	1428
(VI) Depreciation, Depletion & Amortisation	339	338	192
(VII) Impairment	0	0	0
(VIII) PROFIT BEFORE FINANCE COST/INTEREST, EXCEPTIONAL, EXTRA-ORDINARY ITEMS & TAXES (PBIET)(V-VI-VII)	3064	1748	1236
(IX) Finance Cost			
(a) On Central Government Loans	0	0	0
(b) On Foreign Loans	0	0	0
(c) Others	45	15	29
(d) Less Finance Cost Capitalised	0	0	0
(e) Charged to P & L Account (a+b+c -d)	45	15	29
(X) PROFIT BEFORE EXCEPTIONAL & EXTRA-ORDINARY ITEMS & TAX (PBEET)(VIII-IXe)	3019	1733	1207
(XI) Exceptional Items	0	0	0
(XII) PROFIT BEFORE EXTRA-ORDINARY ITEMS & TAX (PBET)(X-XI)	3019	1733	1207
(XIII) Extra-Ordinary Items	0	0	0
(XIV) PROFIT BEFORE TAX (PBT)(XII-XIII)	3019	1733	1207
(XV) TAX PROVISIONS	1068	627	431
(XVI) NET PROFIT / LOSS FOR THE PERIOD FROM CONTINUING OPERATIONS AFTER TAX(XIV-XV)	1951	1106	776
(XVII) Profit/Loss from discontinuing operations	0	0	0
(XVIII) Tax expenses of discontinuing operations	0	0	0
(XIX) Profit/Loss from discontinuing operations (after Tax)(XVII-XVIII)	0	0	0
(XX) Profit/Loss for the period (XVI+XIX)	1951	1106	776
Financial Ratios			
(i) Sales : Capital Employed	238.35	205.16	219.4
(ii) Cost of Sales : Sales	90.69	94.68	96.47
(iii) Salary/Wages : Sales	19.22	22.46	22.1
(iv) Net Profit : Net Worth	15.26	9.99	7.56
(v) Debt : Equity	0.23	0.35	0.31
(vi) Current Ratio	1.85	1.81	1.67
(vii) Trade Recievables : Sales	26.06	27.11	29.86
(viii) Total Inventory : Sales	14.67	21.32	16.05

ONGC Mangalore Petrochemicals Limited

Mangalore Special Economic Zone, Permude, Mangluru-574 509, Karnataka
www.ompl.co.in

The Company

ONGC Mangalore Petrochemicals Limited (OMPL) a green field petrochemicals projects, is promoted by Oil and Natural Gas Corporation Ltd. (ONGC) and Mangalore Refinery and Petrochemicals Limited (MRPL), a subsidiary of ONGC. OMPL has become a direct subsidiary of MRPL w.e.f. 28th February 2015.

OMPL is an 'Uncategorised' CPSE in Chemicals & Pharmaceuticals sector under the administrative control of Ministry of Petroleum & Natural Gas. MRPL holds 51% and ONGC holds 49% of equity share capital of OMPL. The Company employed 465 regular employees (Executives 167 & Non-Executives 298) as on 31.3.2016. Its registered office is at Mangluru, Karnataka.

Vision / Mission

The vision of the company is to be a world class leader in petrochemicals industry.

The mission of the company is to provide quality products and services by means of continuous innovation, learning and operational excellence, maintaining highest standards of safety, health and environmental Protection and sustaining maximum value for stakeholders.

Industrial / Business Operations

OMPL has set up an Aromatic Complex in the Mangalore Special Economic Zone (MSEZ), which is fully integrated with MRPL by sourcing its feedstock to produce Para-xylene (PX) and Benzene (BZ). The Complex is the largest single stream unit in Asia to produce 914 KTPA Para-xylene and 283 KTPA Benzene.

Performance Highlights

The company earned a total revenue of ₹4188.86 crore during 2015-16 and reported a loss of ₹(-) 875.35 crore in 2015-16. The current ratio of company is at 0.16:1 during 2015-16. Balance Sheet and Profit & Loss Account of the company and selected financial ratios during the period 2015-16 can be seen on the adjoining page.

ONGC MANGALORE PETROCHEMICALS LTD.

BALANCE SHEET	(₹ in Lakhs)		
PARTICULARS	2015-16	2014-15	2013-14
I. EQUITY & LIABILITIES		-	-
AUTHORISED CAPITAL	200000	-	-
(1) Shareholders' Funds		-	-
(a) Share Capital		-	-
(i) Central Govt	187763	-	-
(ii) Others	0	-	-
(b) Reserves & Surplus	-140741	-	-
(c) Money received against share warrants	0	-	-
Total Shareholders' Funds (1(a)+1(b)+1(c))	47022	-	-
(2) Share application money pending allotment	0	-	-
(3) Non-current Liabilities		-	-
(a) Long Term Borrowings	215941	-	-
(b) Deferred tax liabilities (Net)	0	-	-
(c) Other Long-term liabilities	0	-	-
(d) Long-term provisions	403	-	-
Total Non-Current Liabilities 3(a) to 3(d)	216344	-	-
(4) Current Liabilities		-	-
(a) Short Term Borrowings	382762	-	-
(b) Trade Payables	47011	-	-
(c) Other current liabilities	72863	-	-
(d) Short-term provisions	25	-	-
Total Current Liabilities 4(a) to 4(d)	502661	-	-
TOTAL EQUITY & LIABILITIES (1+2+3+4)	766027	-	-
II. ASSETS			
(1) Non-Current Assets			
(a) Total Gross Fixed Assets	721136	-	-
(ai) Accumulated Depreciation, Depletion & Amortisation	46601	-	-
(aii) Accumulated Impairment	0	-	-
(b) Total Net Fixed Assets ((a)-(ai)-(aii))	674535	-	-
(c) Capital work in progress	990	-	-
(d) Intangible assets under developmet	0	-	-
(e) Non-Current Investments	48	-	-
(f) Deferred Tax Assets (Net)	0	-	-
(g) Long Term Loans and Advances	9344	-	-
(h) Other Non-Current Assets	0	-	-
Total Non-Current Assets (b+c+d+e+f+g+h)	684917	-	-
(2) Current Assets		-	-
(a) Current Investments	0	-	-
(b) Inventories	22024	-	-
(c) Trade Recievables	15940	-	-
(d) Cash & Bank Balance	9621	-	-
(e) Short-term Loans & Advances	33497	-	-
(f) Other Current Assets	28	-	-
Total Current Assets (a+b+c+d+e+f)	81110	-	-
TOTAL ASSETS (1+2)	766027	-	-
Important Indicators		-	-
(i) Investment	403704	-	-
(ii) Capital Employed	262963	-	-
(iii) Net Worth	47022	-	-
(iv) Net Current Assets	-421551	-	-
(v) Cost of Sales	457725	-	-
(vi) Net Value Added (at market price)	-34773	-	-
(vii) Total Regular Employees (Nos.)	465	-	-
(viii) Avg. Monthly Emoluments per Employee(₹)	67634	-	-

PROFIT & LOSS ACCOUNT	(₹ in Lakhs)		
PARTICULARS	2015-16	2014-15	2013-14
(I) Revenue from Operations (Gross)	418757	-	-
Less : Excise Duty	0	-	-
Revenue from Operations (Net)	418757	-	-
(II) Other Income	129	-	-
(III) Total Revenue (I+II)	418886	-	-
(IV) Expenditure on:		-	-
(a) Cost of materials consumed	360434	-	-
(b) Purchase of stock-in-trade	0	-	-
(c) Changes in inventories of finished goods, work-in-progress and stock in trade	12580	-	-
(d) Stores & Spares	1003	-	-
(e) Power & Fuel	41495	-	-
(f) Salary, Wages & Benefits/Employees Expense	3774	-	-
(g) Other Operating/direct/manufacturing Expenses	1941	-	-
(h) Rent, Royalty & Cess	244	-	-
(i) Loss on sale of Assets/Investments	0	-	-
(j) Other Expenses	5380	-	-
Total Expenditure (IV (a to j))	426851	-	-
(V) PROFIT BEFORE DEPRECIATION, & IMPAIRMENT, FINANCE CHARGES/INTEREST, EXCEPTIONAL & EXTRAORDINARY ITEMS & TAXES (PBDIET)(III-IV)	-7965	-	-
(VI) Depreciation, Depletion & Amortisation	30874	-	-
(VII) Impairment	0	-	-
(VIII) PROFIT BEFORE FINANCE COST/INTEREST, EXCEPTIONAL, EXTRA-ORDINARY ITEMS & TAXES (PBIET)(V-VI-VII)	-38839	-	-
(IX) Finance Cost		-	-
(a) On Central Government Loans	10080	-	-
(b) On Foreign Loans	0	-	-
(c) Others	38616	-	-
(d) Less Finance Cost Capitalised	0	-	-
(e) Charged to P & L Account (a+b+c-d)	48696	-	-
(X) PROFIT BEFORE EXCEPTIONAL & EXTRA-ORDINARY ITEMS & TAX (PBEET)(VIII-IXe)	-87535	-	-
(XI) Exceptional Items	0	-	-
(XII) PROFIT BEFORE EXTRA-ORDINARY ITEMS & TAX (PBET)(X-XI)	-87535	-	-
(XIII) Extra-Ordinary Items	0	-	-
(XIV) PROFIT BEFORE TAX (PBT)(XII-XIII)	-87535	-	-
(XV) TAX PROVISIONS	0	-	-
(XVI) NET PROFIT / LOSS FOR THE PERIOD FROM CONTINUING OPERATIONS AFTER TAX(XIV-XV)	-87535	-	-
(XVII) Profit/Loss from discontinuing operations	0	-	-
(XVIII) Tax expenses of discontinuing operations	0	-	-
(XIX) Profit/Loss from discontinuing operations (after Tax)(XVII-XVIII)	0	-	-
(XX) Profit/Loss for the period (XVI+XIX)	-87535	-	-
Financial Ratios		-	-
(i) Sales : Capital Employed	159.25	-	-
(ii) Cost of Sales : Sales	109.31	-	-
(iii) Salary/Wages : Sales	0.9	-	-
(iv) Net Profit : Net Worth	-186.16	-	-
(v) Debt : Equity	1.15	-	-
(vi) Current Ratio	0.16	-	-
(vii) Trade Recievables : Sales	3.81	-	-
(viii) Total Inventory : Sales	5.26	-	-

Orissa Drugs & Chemicals Ltd.

1, Mancheswar Industrial Estate, Bhubaneswar-751010

http://chemicals.nic.in/pharma_odcl.htm

The Company

Orissa Drugs & Chemicals Ltd. (ODCL) was incorporated on 01.05.1979 as a joint venture of Indian Drugs & Pharmaceuticals Ltd. (IDPL) and Industrial Promotion and Investment Corporation of Orissa Limited (IPICOL) having share 51% and 49% respectively with the objective to manufacture and supply quality life saving drugs to the State Government of Orissa and adjoining States at reasonable price. The company started its commercial production in September, 1983.

ODCL is a schedule 'D' BIFR referred CPSE in Chemicals & Pharmaceuticals sector under the administrative control of M/o Chemicals and Fertilizers, D/o Pharmaceuticals. The company employed 61 Regular employees (Executives-10 & Non-Executives-51) as on 31.3.2016. Its registered and corporate offices are at Bhubaneswar, Orissa.

Industrial / Business Operations

ODCL is involved in manufacturing of 247 pharmaceutical formulations in the form of Tablets, Capsules, Injections, Powder and Liquid orals through its single operating unit at Bhubaneswar in Orissa.

Performance Highlights

The physical performance of the company during the last three years is given below:

Main Products / Services	Unit	Performance during (in Lakhs)		
		2015-16	2014-15	2013-14
Tablet	10X10	1140	786	685
Capsules	10X10	403	425	394
Injection	No. ML.	70	67	21
ORS	No.	37	50	18

Total revenue of the company registered an increase of ₹1.32 crore during 2015-16, which went up to ₹20.41 crore in 2015-16 from ₹19.09 crore in 2014-15 (Fig.1). The profit of the company has gone up by ₹0.11 crore to ₹1.46 crore in 2015-16, from ₹1.35 crore in previous year due to increase in revenue.

The net worth of company is negative. The net profit ratio of the company is at 7.15% in 2015-16 as against of 7.07% in 2014-15 (Fig.2). The current ratio of company is at 0.88:1 during 2015-16 as against 0.72:1 in the previous year. Balance Sheet and Profit & Loss Account of the company and selected financial ratios during the period 2013-14 to 2015-16 can be seen on the adjoining page.




Fig.1




Fig.2

Strategic issues

BIFR passed orders for winding up in April, 2003 under the provisions of SICA Act, 1985. High Court of Orissa had appointed a provisional Liquidator. This has since been stayed by a larger Bench of the Odisha High Court.

ORISSA DRUGS & CHEMICALS LTD.

BALANCE SHEET	(₹ in Lakhs)		
PARTICULARS	2015-16	2014-15	2013-14
I. EQUITY & LIABILITIES			
AUTHORISED CAPITAL	160	160	160
(1) Shareholders' Funds			
(a) Share Capital			
(i) Central Govt	0	0	0
(ii) Others	132	132	132
(b) Reserves & Surplus	-1552	-1698	-1636
(c) Money received against share warrants	0	0	0
Total Shareholders' Funds (1(a)+1(b)+1(c))	-1420	-1566	-1504
(2) Share application money pending allotment	17	17	17
(3) Non-current Liabilities			
(a) Long Term Borrowings	1646	1606	1509
(b) Deferred tax liabilities (Net)	0	0	0
(c) Other Long-term liabilities	0	0	472
(d) Long-term provisions	0	0	0
Total Non-Current Liabilities 3(a) to 3(d)	1646	1606	1981
(4) Current Liabilities			
(a) Short Term Borrowings	225	230	230
(b) Trade Payables	307	282	169
(c) Other current liabilities	778	792	31
(d) Short-term provisions	0	0	0
Total Current Liabilities 4(a) to 4(d)	1310	1304	430
TOTAL EQUITY & LIABILITIES (1+2+3+4)	1553	1361	924
II. ASSETS			
(1) Non-Current Assets			
(a) Total Gross Fixed Assets	590	584	519
(ai) Accumulated Depreciation, Depletion & Amortisation	192	167	156
(aii) Accumulated Impairment	0	0	0
(b) Total Net Fixed Assets ((a)-(ai)-(aii))	398	417	363
(c) Capital work in progress	0	0	0
(d) Intangible assets under developmet	0	0	0
(e) Non-Current Investments	0	0	0
(f) Deferred Tax Assets (Net)	0	0	0
(g) Long Term Loans and Advances	0	0	0
(h) Other Non-Current Assets	0	0	0
Total Non-Current Assets (b+c+d+e+f+g+h)	398	417	363
(2) Current Assets			
(a) Current Investments	0	0	0
(b) Inventories	390	276	355
(c) Trade Recievables	598	581	77
(d) Cash & Bank Balance	70	87	129
(e) Short-term Loans & Advances	97	0	0
(f) Other Current Assets	0	0	0
Total Current Assets (a+b+c+d+e+f)	1155	944	561
TOTAL ASSETS (1+2)	1553	1361	924
Important Indicators			
(i) Investment	1795	1755	1658
(ii) Capital Employed	243	57	22
(iii) Net Worth	-1403	-1549	-1487
(iv) Net Current Assets	-155	-360	131
(v) Cost of Sales	1850	1729	1357
(vi) Net Value Added (at market price)	544	496	335
(vii) Total Regular Employees (Nos.)	61	61	64
(viii) Avg. Monthly Emoluments per Employee(₹)	31694	28552	26042
2015-16 PROVISIONAL			

PROFIT & LOSS ACCOUNT	(₹ in Lakhs)		
PARTICULARS	2015-16	2014-15	2013-14
(I) Revenue from Operations (Gross)	2124	1909	1469
Less : Excise Duty	83	0	0
Revenue from Operations (Net)	2041	1909	1469
(II) Other Income	0	0	0
(III) Total Revenue (I+II)	2041	1909	1469
(IV) Expenditure on:			
(a) Cost of materials consumed	1108	1044	807
(b) Purchase of stock-in-trade	0	0	0
(c) Changes in inventories of finished goods, work-in-progress and stock in trade	0	0	7
(d) Stores & Spares	5	4	4
(e) Power & Fuel	30	20	30
(f) Salary, Wages & Benefits/Employees Expense	232	209	200
(g) Other Operating/direct/manufacturing Expenses	449	441	296
(h) Rent, Royalty & Cess	2	2	0
(i) Loss on sale of Assets/Investments	0	0	0
(j) Other Expenses	1	1	2
Total Expenditure (IV (a to j))	1827	1721	1346
(V) PROFIT BEFORE DEPRECIATION, & IMPAIRMENT, FINANCE CHARGES/INTEREST, EXCEPTIONAL & EXTRAORDINARY ITEMS & TAXES (PBDIET)(III-IV)	214	188	123
(VI) Depreciation, Depletion & Amortisation	23	8	11
(VII) Impairment	0	0	0
(VIII) PROFIT BEFORE FINANCE COST/INTEREST, EXCEPTIONAL, EXTRA-ORDINARY ITEMS & TAXES (PBIET)(V-VI-VII)	191	180	112
(IX) Finance Cost			
(a) On Central Government Loans	0	0	0
(b) On Foreign Loans	0	0	0
(c) Others	45	45	63
(d) Less Finance Cost Capitalised	0	0	0
(e) Charged to P & L Account (a+b+c -d)	45	45	63
(X) PROFIT BEFORE EXCEPTIONAL & EXTRA-ORDINARY ITEMS & TAX (PBEET)(VIII-IXe)	146	135	49
(XI) Exceptional Items	0	0	0
(XII) PROFIT BEFORE EXTRA-ORDINARY ITEMS & TAX (PBET)(X-XI)	146	135	49
(XIII) Extra-Ordinary Items	0	0	0
(XIV) PROFIT BEFORE TAX (PBT)(XII-XIII)	146	135	49
(XV) TAX PROVISIONS	0	0	0
(XVI) NET PROFIT / LOSS FOR THE PERIOD FROM CONTINUING OPERATIONS AFTER TAX(XIV-XV)	146	135	49
(XVII) Profit/Loss from discontinuing operations	0	0	0
(XVIII) Tax expenses of discontinuing operations	0	0	0
(XIX) Profit/Loss from discontinuing operations (after Tax)(XVII-XVIII)	0	0	0
(XX) Profit/Loss for the period (XVI+XIX)	146	135	49
Financial Ratios			
(i) Sales : Capital Employed	839.92	3349.12	6677.27
(ii) Cost of Sales : Sales	90.64	90.57	92.38
(iii) Salary/Wages : Sales	11.37	10.95	13.61
(iv) Net Profit : Net Worth	-	-	-
(v) Debt : Equity	11.05	10.78	10.13
(vi) Current Ratio	0.88	0.72	1.3
(vii) Trade Recievables : Sales	29.3	30.43	5.24
(viii) Total Inventory : Sales	19.11	14.46	24.17

Rajasthan Drugs & Pharmaceuticals Ltd.

Road No. 12, V.K.I Area, Jaipur-302013

www.rdpl-india.in

The Company

Rajasthan Drugs & Pharmaceuticals Ltd. (RDPL) was incorporated on 02-11-1978 with an objective to supply lifesaving and other essential drugs to the State Government Medical Health Departments and other Govt. Institutions.

RDPL was a subsidiary of IDPL. However as per revival plan of RDPL, 51% equity shares held by IDPL in the share capital of the RDPL was transferred to President of India on 17.08.2010. Further allotments of equity shares worth ₹200 lakhs and ₹192 lakhs were made to the President of India and Rajasthan Industrial Development and Investment Corporations (RIICO Ltd.) respectively. 51.04% of equity is now held by Govt. of India and 48.96% by RIICO Ltd, respectively and RDPL is no longer a subsidiary of IDPL.

RDPL is a schedule 'D' CPSE in Chemicals & Pharmaceuticals sector under the administrative control of M/o Chemicals and Fertilizers, D/o Pharmaceuticals. Its Registered and Corporate offices are at Jaipur, Rajasthan. The company employed 160 Regular employees (Executives 24 & Non-Executives 136) as on 31.3.2016.

Vision / Mission

The vision of the company is to achieve excellence in the field of manufacturing and marketing of quality drugs & health care products at affordable prices of all.

The mission of the Company is to improve in house facilities to manufacture essential medicines (Generic and Branded medicines) for supply to Government organizations as well as for Open Market, at reasonable prices, to continuously improve the Quality of Products and Services to enhance Customer Satisfaction, to develop highly motivated multi skilled Human Resources to increase Productivity and to meet emergency need of the country for supply of Medicines during Natural Calamities like Epidemics, Earthquakes, Floods and in Disaster Management.

Industrial / Business Operations

RDPL is engaged in manufacturing and selling of drugs & pharmaceuticals to Government of Rajasthan, Central government Institutes, viz ESIC, Defence, Railways, other PSUs and also to other state Government institutes. The Company is having one operating unit at Jaipur, Rajasthan. RDPL is a prime partner in the novel endeavor of Government of India in the implementation of 'JANAUSHADHI' programme, where generic medicines are made available to the public at large in the country at affordable price.

Performance Highlights

The physical performance of the company during the last three years is given below:

Main Products	Unit	Performance during		
		2015-16	2014-15	2013-14
Tablets	Million	171.45	142.82	318.08
Capsules	Million	36.21	22.21	93.93
Liquids	K.L	85.39	139.00	239.40
Powder	M.T	37.54	34.81	90.39
Vials/Ampoules	Lac Nos.	-	1.34	2.46

Total revenue of the company registered an increase of ₹11.25 crore during 2015-16, which went up to ₹35.16 crore in 2015-16 from ₹23.91 crore in 2014-15 (Fig.1). The company has incurred a loss of ₹(-) 5.99 crore in 2015-16, as against a loss of ₹(-) 19.76 crore in previous year.

The net worth of the company is negative in the year 2015-16. The net profit ratio of the company is (-) 17.10% in 2015-16 as against (-)83.31% in previous year 2014-15(Fig.2).The current ratio of company is at 0.51:1 during 2015-16 as against 0.50:1 in the previous year. Balance Sheet and Profit & Loss Account of the company and selected financial ratios during the period 2013-14 to 2015-16 can be seen on the adjoining page.




Fig. 1

Strategic issues

In the interest of continued growth and development of the company, Government has delinked RDPL from holding company IDPL (the original promoter). The company has since then enhanced its manufacturing capacities by installing new machines. The company is diversifying its marketing activities into pharma prescription markets, veterinary markets, marketing of ayurvedic and other Indian system of medicines.

The expiry of Preferential Purchase Policy (PPP) of Government of India on 6th August, 2011 and change in PPP of Government of Rajasthan are of great concern to the company's future prospects. However, the renewal of PPP of Government of India w.e.f. October 2013 for a further period of 5 years will help receive bulk orders from Ministry of Health and other Government Institutions.

The proposal for purchase preference policy's continuance by Govt. of Rajasthan in line with similar preference given by Govt. of Karnataka to KAPL, a similarly constituted company, has been submitted to Govt. of Rajasthan, which is yet under their consideration.

The company has devised new marketing strategy under which new C&F agents, Marketing organizers cum Distributors are proposed to be appointed in new territories in near future. They have been geared up to meet higher targets of sales & early realisations.

RAJASTHAN DRUGS & PHARMACEUTICALS LTD.

BALANCE SHEET	₹ in Lakhs		
PARTICULARS	2015-16	2014-15	2013-14
I. EQUITY & LIABILITIES			
AUTHORISED CAPITAL	1000	1000	1000
(1) Shareholders' Funds			
(a) Share Capital			
(i) Central Govt	255	255	255
(ii) Others	244	244	244
(b) Reserves & Surplus	-1784	-1212	-389
(c) Money received against share warrants	0	0	0
Total Shareholders' Funds (1(a)+1(b)+1(c))	-1285	-713	110
(2) Share application money pending allotment	0	0	0
(3) Non-current Liabilities			
(a) Long Term Borrowings	0	0	484
(b) Deferred tax liabilities (Net)	0	0	0
(c) Other Long-term liabilities	294	295	0
(d) Long-term provisions	429	320	0
Total Non-Current Liabilities 3(a) to 3(d)	723	615	484
(4) Current Liabilities			
(a) Short Term Borrowings	1417	1413	1525
(b) Trade Payables	3523	2655	2712
(c) Other current liabilities	778	613	621
(d) Short-term provisions	359	384	651
Total Current Liabilities 4(a) to 4(d)	6077	5065	5509
TOTAL EQUITY & LIABILITIES (1+2+3+4)	5515	4967	6103
II. ASSETS			
(1) Non-Current Assets			
(a) Total Gross Fixed Assets	2223	2221	2211
(ai) Accumulated Depreciation, Depletion & Amortisation	836	729	573
(aii) Accumulated Impairment	0	0	0
(b) Total Net Fixed Assets ((a)-(ai)-(aii))	1387	1492	1638
(c) Capital work in progress	69	44	43
(d) Intangible assets under developmet	0	0	0
(e) Non-Current Investments	0	0	0
(f) Deferred Tax Assets (Net)	180	180	180
(g) Long Term Loans and Advances	758	727	769
(h) Other Non-Current Assets	0	0	0
Total Non-Current Assets (b+c+d+e+f+g+h)	2394	2443	2630
(2) Current Assets			
(a) Current Investments	0	0	0
(b) Inventories	500	395	623
(c) Trade Recievables	1801	1159	2572
(d) Cash & Bank Balance	752	899	224
(e) Short-term Loans & Advances	51	51	45
(f) Other Current Assets	17	20	9
Total Current Assets (a+b+c+d+e+f)	3121	2524	3473
TOTAL ASSETS (1+2)	5515	4967	6103
Important Indicators			
(i) Investment	499	499	983
(ii) Capital Employed	-1285	-713	594
(iii) Net Worth	-1285	-713	110
(iv) Net Current Assets	-2956	-2541	-2036
(v) Cost of Sales	3889	3170	5455
(vi) Net Value Added (at market price)	886	-441	-126
(vii) Total Regular Employees (Nos.)	160	171	184
(viii) Avg. Monthly Emoluments per Employee(₹)	60677	62476	61821

PROFIT & LOSS ACCOUNT	₹ in Lakhs		
PARTICULARS	2015-16	2014-15	2013-14
(I) Revenue from Operations (Gross)	3653	2490	4350
Less : Excise Duty	150	118	230
Revenue from Operations (Net)	3503	2372	4120
(II) Other Income	13	19	23
(III) Total Revenue (I+II)	3516	2391	4143
(IV) Expenditure on:			
(a) Cost of materials consumed	1497	1249	2701
(b) Purchase of stock-in-trade	736	-21	553
(c) Changes in inventories of finished goods, work-in-progress and stock in trade	-119	55	6
(d) Stores & Spares	15	5	32
(e) Power & Fuel	57	48	88
(f) Salary, Wages & Benefits/Employees Expense	1165	1282	1365
(g) Other Operating/direct/manufacturing Expenses	423	351	593
(h) Rent, Royalty & Cess	2	6	14
(i) Loss on sale of Assets/Investments	0	0	0
(j) Other Expenses	5	39	3
Total Expenditure (IV (a to j))	3781	3014	5355
(V) PROFIT BEFORE DEPRECIATION, & IMPAIRMENT, FINANCE CHARGES/INTEREST, EXCEPTIONAL & EXTRAORDINARY ITEMS & TAXES (PBDIET)(III-IV)	-265	-623	-1212
(VI) Depreciation, Depletion & Amortisation	108	156	100
(VII) Impairment	0	0	0
(VIII) PROFIT BEFORE FINANCE COST/INTEREST, EXCEPTIONAL, EXTRA-ORDINARY ITEMS & TAXES (PBIET)(V-VI-VII)	-373	-779	-1312
(IX) Finance Cost			
(a) On Central Government Loans	0	0	0
(b) On Foreign Loans	0	0	0
(c) Others	226	214	252
(d) Less Finance Cost Capitalised	0	0	0
(e) Charged to P & L Account (a+b+c -d)	226	214	252
(X) PROFIT BEFORE EXCEPTIONAL & EXTRA-ORDINARY ITEMS & TAX (PBEET)(VIII-IXe)	-599	-993	-1564
(XI) Exceptional Items	0	983	380
(XII) PROFIT BEFORE EXTRA-ORDINARY ITEMS & TAX (PBET)(X-XI)	-599	-1976	-1944
(XIII) Extra-Ordinary Items	0	0	0
(XIV) PROFIT BEFORE TAX (PBT)(XII-XIII)	-599	-1976	-1944
(XV) TAX PROVISIONS	0	0	-4
(XVI) NET PROFIT / LOSS FOR THE PERIOD FROM CONTINUING OPERATIONS AFTER TAX(XIV-XV)	-599	-1976	-1940
(XVII) Profit/Loss from discontinuing operations	0	0	0
(XVIII) Tax expenses of discontinuing operations	0	0	0
(XIX) Profit/Loss from discontinuing operations (after Tax)(XVII-XVIII)	0	0	0
(XX) Profit/Loss for the period (XVI+XIX)	-599	-1976	-1940
Financial Ratios			
(i) Sales : Capital Employed	-272.61	-332.68	693.6
(ii) Cost of Sales : Sales	111.02	133.64	132.4
(iii) Salary/Wages : Sales	33.26	54.05	33.13
(iv) Net Profit : Net Worth	-	-	1763.64
(v) Debt : Equity	0	0	0.97
(vi) Current Ratio	0.51	0.5	0.63
(vii) Trade Recievables : Sales	51.41	48.86	62.43
(viii) Total Inventory : Sales	14.27	16.65	15.12